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II. Summary 
 
Recent years have witnessed a resurgence in tumor metabolism research. Cancer cells are 
known to exhibit multiple distinct aberrations in energy-utilization that help them sustain rapid 
growth and proliferation, as well as cope with harsh microenvironment conditions, such as 
limited nutrient availability and oxygenation. Amplified growth factor and oncogenic signaling 
have been implicated in the observed metabolic reprogramming in cancers, and thus, drugs that 
target these signaling aberrations have also been shown to impact metabolism. Furthermore, 
several drugs have been developed or repurposed to interfere with metabolic processes in 
transformed cells. In this thesis, the results of my investigations into the ability of 1,25-
dihydroxyvitamin D3 [1,25(OH)2D3] (also referred to as calcitriol)—the hormonally active 
form of vitamin D3—to influence metabolic pathways in different cancer models are presented. 
Using prostate cancer cell lines with different androgen sensitivities, as well as breast cancer 
cell lines representing different molecular subtypes, it is shown that 1,25(OH)2D3 is a major 
regulator of energy-utilization and glucose-sensing networks in these cancer cells. Detailed 
investigation of cellular metabolism using biosensor technology, GC/MS-based metabolomics, 
RT-qPCR gene expression analyses, enzymatic activity assays, FACS analyses, and 
immunoblotting, illustrates that 1,25(OH)2D3 induces global rewiring of glucose-metabolizing 
pathways, as well as modulates energy-related signaling molecules including AMP-activated 
protein kinase and thioredoxin-interacting protein (TXNIP). My results also show, that in 
contrast to the long-standing association between TXNIP and calcitriol, the former is not 
universally regulated by the latter in cancer cell lines of various tissue origins, and that the 
canonical regulation is subject to glucose-availability. In conclusion, I like to propose that 
regulation of onco-metabolism is a mechanism through which calcitriol induces its anti-cancer 
effects, and argue that continued investigations into this theme would elucidate ways to improve 
the molecule’s therapeutic potential.  
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III. Zusammenfassung 
 
Im letzten Jahrzehnt ist ein wiederauflebendes Interesse an der Erforschung der 
Stoffwechselwege von Krebszellen entstanden. Krebszellen weisen diverse Unterschiede bei 
der Energienutzung auf, wodurch sie eine schnelle und starke Proliferation zu erzielen. Des 
Weiteren, helfen diese Stoffwechsanpassungen Krebszellen in rauen 
Mikroumgebungsbedingungen zu überleben, wie begrenzte Nährstoffverfügbarkeit und 
Sauerstoffversorgung. Eine entscheidende Rolle im veränderten Stoffwechsel von Krebszellen 
spielt die erhöhte Ausschüttung an Wachstumsfaktoren und onkogenen Signalen. 
Krebsmedikamente, die diese Faktoren beeinflussen haben oftmals einen veränderten zellulären 
Metabolismus zur Folge. In diesem Zusammenhang wurden verschiedene Medikamente 
entwickelt oder umfunktioniert, um die Stoffwechselprozesse in Krebszellen zu stören. In der 
vorliegenden Dissertation werden Untersuchungen zur Fähigkeit von 1,25-Dihydroxyvitamin 
D3 [1,25(OH)2D3] Stoffwechselwege in verschiedene Krebsmodelle zu beeinflussen 
präsentiert.  1,25(OH)2D3 ist die hormonell aktive Form von Vitamin D und wird auch als 
Calcitriol bezeichnet. Unter Verwendung von Prostatakrebszelllinien mit verschiedenen 
Androgensensitivitäten und zwei molekularen Subtypen von Brustkrebszellen, konnte 
nachgewiesen werden, dass 1,25(OH)2D3 ein Hauptregulator der Energienutzung und 
Glukosewahrnehmung Krebszellen ist. Die mit Biosensortechnologie, GC / MS-basierter 
Metabolomik, Genexpressionsanalysen mit RT-qPCR, enzymatischen Aktivitätsassays, FACS-
Analysen und Immunoblotting, erhaltenen Daten, zeigen klar den Einfluss von 
1,25(OH)2D3 auf den Glukosestoffwechselweg und verschiedene Energie-Signalmoleküle wie 
der AMP-aktivierte Proteinkinase und dem Thioredoxin-interagierende Protein 
(TXNIP).  Überraschender Weise, konnte entgegen der langjährig etablierten Assoziation 
zwischen TXNIP und Calcitriol gezeigt werden, dass TXNIP nicht in allen Krebszelllinien 
verschiedener Gewebeursprünge universell durch Calcitriol reguliert wird sondern vor allem in 
Abhängigkeit der Verfügbarkeit von Glukose reguliert wird. Letztendlich schlage ich vor, dass 
sich ein Teil der Anti-Krebs-Wirkung von Calcitriol durch die Regulation des Onko-
Metabolismus erklären lässt und weitere Forschung in dies Richtung neue Wege aufzeigen 
kann, wie das therapeutische Potenzial von Calcitriol besser genutzt werden kann.  
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1. INTRODUCTION 
 
1.1. Vitamin D and human health 
 
Our understanding of vitamin D and its effects on humans has gone a long way since the 
investigations early in the twentieth century that aimed at discovering the anti-rachitic 
component of cod liver oil. Although the German steroid chemist Adolf Windaus was awarded 
the Nobel prize in Chemistry for his work on the “constitution of sterols and their connection 
with vitamins” in 1928 [1], research in the vitamin D field had stagnated for years before a 
series of landmark discoveries brought the molecule back in the limelight (Figure 1).  
 
 
Figure 1: PubMed/MEDLINE search using “vitamin D” as a keyword. An exponential 
increase in the number of publications on vitamin D is observed towards the end of the twentieth 
century, with the number of publications on this topic surpassing doubling between 2005 and 
2015. 
 
Despite the classification as a vitamin, adequate and regular exposure to sunlight, precisely UV-
B, is proposed to provide humans with sufficient vitamin D levels without the need for dietary 
supplementation [2]. Vitamin D is a fat-soluble vitamin that exists in two forms, D3 
(cholecalciferol) and D2 (ergocalciferol) [3]. Bound to its binding protein, vitamin D is 
transported to the liver, the site of the first hydroxylation step, occurring at the 25-position [4]. 
The identity of the enzyme catalyzing this step has been contentious, however, recent evidence 
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has illustrated that the cytochrome P450 (CYP) 2R1 enzyme is a major vitamin D-25-
hydroxylase [5]. The resulting metabolite, 25-hydroxyvitamin D, is the major circulating 
metabolite, and is currently used as the biomarker for vitamin D status in the clinic [6]. The 
second metabolizing/activating step takes place mainly in the kidneys, and is catalyzed by the 
25-hydroxyvitamin D-1-hydroxylase, CYP27B1, which yields the bioactive form of the 
vitamin, 1,25-dihydroxyvitamin D [1,25(OH)2D3], also known as calcitriol [4]. Subsequently, 
the molecule binds to the nuclear vitamin D receptor (VDR) present in target cells, triggering 
its hetero-dimerization with retinoid X receptor (RXR), leading to binding to vitamin D 
response elements (VDRE) on promoters of target genes, including those involved in calcium 
homeostasis [4]. An increase in the levels of calcitriol induces the expression of CYP24A1, the 
catabolizing enzyme that converts the molecule to reduced activity metabolites [7].   
 
In view of this, vitamin D had been mainly thought of as a major regulator of skeletal health, 
however, recent findings have reshaped this classical notion, including the identification of 
VDRs as well as the enzymatic machinery required for vitamin D metabolism and bio-
activation in diverse types of cells [3]. In other words, in addition to acting in an endocrine 
fashion, vitamin D also works in an autocrine manner [4]. It is therefore conceivable that the 
molecule plays multiple roles in these non-classical target cells. Additionally, besides genomic 
effects, an increasing number of studies has demonstrated that 1,25(OH)2D3 also induces rapid, 
non-genomic effects, such as rapid calcium absorption (transcaltachia), as well as insulin 
secretion [8].  
 
Further supporting the proposed extra-skeletal effects of vitamin D are the epidemiological data 
demonstrating a correlation between suboptimal vitamin D levels and a myriad of chronic 
diseases, including cardiovascular disease, autoimmune diseases, and cancers [3, 4]. Based on 
this evidence, researchers worldwide have initiated numerous clinical trials to assess the 
therapeutic utility of the molecule against these diseases [9]. Of interest is the fact that 
guidelines for vitamin D supplementation as well as vitamin D status classification, issued by 
the Institute of Medicine and the Endocrine Society are different [9].   
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1.2. Vitamin D and cancer 
 
1.2.1. Epidemiology 
 
Over the years, many studies have linked vitamin D deficiency to increased incidence and poor 
prognosis of cancer [3, 4, 9]. Reports highlighting this potential date back to the 1980s [10], in 
which investigators observed an inverse correlation between UV radiation and the incidence of 
cancer. Since then, plentiful observational studies have demonstrated an inverse correlation 
between vitamin D status and different cancers [4, 9]. However, randomized-controlled trials 
evaluating the usefulness of vitamin D in reducing cancer risk have been so far inconclusive, at 
least in part due to insufficient dosing used [11]. Moreover, limitations of many conducted 
clinical trials include: i) associating health outcomes with vitamin D intake rather than 
circulating concentrations of 25(OH)D, ii) assuming that the clinical trial is the only source of 
the molecule for the subjects, which is typically the case with pharmaceuticals, and iii) 
recruiting subjects independent of baseline 25(OH)D levels, i.e. subjects may not be vitamin D 
deficient in the first place [11].   
 
Despite this, several clinical trials have reported beneficial outcomes with vitamin D 
supplementation, an example of which is the Women’s Health Initiative, in which the 
investigators described reduced incidence of total, as well as breast and invasive breast cancers, 
in women receiving vitamin D and calcium supplement, provided they did not initially receive 
personal vitamin D and calcium supplementation [12]. 
 
A recently conducted genome-wide association study has demonstrated a connection between 
single nucleotide polymorphisms (SNPs) in genes involved in the vitamin D pathway and 25-
hydroxyvitamin D levels in subjects of European descent [13]. Genes implicated in these 
studies include DHCR7 (7-dehydrocholesterol reductase), GC (group-specific component), and 
CYP2R1 [13]. The first gene encodes an enzyme that converts 7-dehydrocholesterol to 
cholesterol, which is the last step in the cholesterol biosynthetic pathway [13]. Since 7-
dehydrocholesterol is the starting molecule for vitamin D3 photosynthesis in the skin, a clear 
connection between polymorphisms in the DHCR7 gene and 25-hydroxyvitamin D levels could 
be drawn, on the basis that an altered enzymatic activity associated with a particular genetic 
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variant may influence the levels of its substrate available for vitamin D3 production. The GC 
gene on the other hand encodes the vitamin D binding protein, which functions as a transporter 
of vitamin D and its metabolites [13]. SNPs in this gene have been shown to influence the 
affinity of the protein to its cargo molecules, as well as overall levels of the protein, thus 
impacting total and bioavailable/free 25-hydroxyvitamin D levels [14]. Given the correlation 
of SNPs in these genetic loci with vitamin D status, several studies have explored their 
association with different diseases including cancers, however, such investigations have 
reported conflicting associations with cancer risk [15-17].  
 
In addition to genetic polymorphisms, alterations in the expression level of vitamin D genes, 
such as the VDR, CYP27B1, and CYP24A1 genes, have been reported [9]. For example, 
CYP24A1 amplification has been observed in cancer cells, which may influence the efficacy 
of vitamin D-based therapies [9]. Treatment of tumor cells with CYP inhibitors in combination 
with calcitriol has been shown to enhance the latter’s anti-cancer potential [18, 19], however, 
it should be noted that inhibiting the degradation of vitamin D metabolites may also augment 
unwanted calcemic effects. Alterations in the expression of CYP27B1 on the other hand have 
been shown to be influenced by the tumor grade and the extent of cellular differentiation [20]. 
Moreover, elevated VDR expression in prostate [21], breast [22], and colorectal cancer [23] 
cells has been linked to better prognosis in patients.     
  
1.2.2. Molecular mechanisms 
 
The discovery of calcitriol’s ability to exert anti-cancer effects originates from two articles 
published in 1981, in which the authors of the first report described the anti-proliferative effect 
of the molecule in malignant melanoma cells [24], and the induction of differentiation in 
myeloid leukemia cells in the second one [25].  
 
The now known anti-cancer effects calcitriol and its analogs induce in tumor cells are diverse, 
and new properties are frequently reported in the literature [7, 9]. Vitamin D compounds have 
been shown to modulate different pathways aberrantly regulated in cancers, including cell cycle 
control and proliferation, as well as differentiation and inflammation [9]. Additionally, 
calcitriol possesses a myriad of tissue-specific anti-cancer effects, such as induction of 
differentiation in myeloid leukemia and prostate cancer cells, hampering of estrogen signaling 
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in breast cancer cells, and inhibition of the Wnt/ β-catenin signaling pathway in colon cancer 
cells [9]. 
 
Other more “general” effects have also been observed in multiple tumor types such as induction 
of the cell cycle inhibitor p21, and reduction in the MYC oncogene, both of which are reported 
vitamin D target genes [26, 27]. Furthermore, with regards to apoptotic signaling, calcitriol has 
been shown to modulate the expression of members of the Bcl2 family of proteins, with the 
expression of anti-apoptotic members, for example Bcl2, downregulated in cancer cells with 
treatment, and pro-apoptotic members, namely BAX, induced [9].  
 
Intriguingly, in cultured prostate cancer cells, calcitriol treatment has been shown to markedly 
induce androgen receptor (AR) expression [28, 29]. While this may appear counter-therapeutic 
since therapies used in prostate cancer management aim to inhibit androgen signaling [30], this 
induction in AR levels by calcitriol in LNCaP cells appears to be critical to the molecule’s anti-
tumor activities. Specifically, it has been shown that culturing these cells in medium 
supplemented with charcoal-stripped serum, or co-treating cells with the AR antagonist casodex 
in normal medium (i.e. supplemented with serum containing endogenous androgens), markedly 
limits calcitriol’s growth-inhibiting effects [31], which altogether indicates that basal AR 
activity is necessary for such anti-tumor activities. Further analyses revealed that the androgen-
induced, proliferation shutdown-associated gene, AS3, was induced by 1,25(OH)2D3 in LNCaP 
cells, and that this induction was abrogated in the presence of casodex [32]. Therefore, these 
findings highlight the potential anti-tumor antagonism of calcitriol and casodex (or other AR 
antagonists), which are otherwise independently potent in androgen-dependent prostate cancer 
cells. 
 
In colorectal cancer cells, the expression levels of the transcription factor SNAIL have been 
shown to influence the efficacy of calcitriol and its analogs, due to its ability to reduce the 
expression of VDR [33]. Moreover, an inverse correlation between SNAIL and VDR 
expression has been reported in human colon cancers, and that colon cancer cells 
overexpressing SNAIL resist EB1089’s (a vitamin D analog) growth inhibiting effects [33]. 
Additionally, SNAIL has been shown to hamper calcitriol’s ability to induce E-cadherin [33]. 
Therefore, SNAIL expression level has been proposed to be a determinant of the success of 
vitamin D compounds in colon cancer treatment [34].   
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1.2.3. Vitamin D in cancer treatment: analogs and combination chemotherapy 
 
A clear setback in vitamin D-based chemotherapy is the supra-physiological doses required to 
elicit potent anti-tumor effects, which may lead to hypercalcemia [35]. To overcome this 
setback, numerous hypo-calcemic vitamin D analogs have been developed with similar, or even 
more potent transactivation potential compared to the parent molecule, in normo-calcemic 
doses [35]. Several analogs have successfully made their way to the clinic, such as calcipotriol, 
which is currently used to treatment psoriasis, the hyper-proliferative skin disorder [35].  
 
Although not completely understood, several studies have aimed at elucidating the underlying 
mechanism of reduced calcemic effects of these vitamin D analogs, and few explanations have 
been provided so far, including: i) altered catabolism, leading to tissue selectivity, since 
different types of cells may promote specific catabolic pathways [35]; and ii) promoter 
selectivity [36], due to differential VDR-RXR stabilization by analogs at different kinds of 
VDREs. For instance, the vitamin D analog EB1089 has been shown to preferentially stabilize 
VDR-RXR at VDREs of the IP9-type, more than at the classical DR3-type [37]. While both 
binding motifs are characterized by two hexameric nucleotide sequences, these sequences are 
inverted palindromic and separated by 9 nucleotides in case of the former, whereas direct 
repeats and separated by 3 nucleotides in case of the latter [36]. Since EB1089 has been shown 
to exert more potent anti-cancer effects than calcitriol, for example in breast cancer cells [38], 
it is possible that genes associated with the molecule’s anti-tumor effects harbor IP9-type 
VDREs. While this notion has not been proven, supporting this possibility is the fact that the 
cell cycle regulator p21, which is a vitamin D-target gene, harbors such motif [39].    
 
A different approach, one that serves both vitamin D-based therapies as well as other 
chemotherapeutics, is combination chemotherapy. This strategy is widely used in oncological 
settings to enhance the efficacy as well as reduce the side effects of the drugs used. In colorectal 
cancer for instance, the use of the FOLFOX regimen, composed of folinic acid, 5-fluorouracil 
(5-FU), and oxaliplatin, has been shown to be therapeutically advantageous compared to mono-
therapies [40]. Investigating the combination of vitamin D compounds with classical and 
repurposed chemotherapeutics is a recurring theme in vitamin D literature, with several 
combinations proposed to be more potent than the corresponding single entities. For example, 
a recent report has illustrated that in animal models of pancreatic ductal adenocarcinoma, 
calcipotriol induces profound transcriptional changes in the tumor stroma, that lead to improved 
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tumoral delivery of the drug gemcitabine, and enhanced survival in animals receiving both 
drugs [41]. Besides this study, numerous reports have combined different VDR activators with 
drugs with diverse mechanisms of action, such as anti-metabolites [42], platins [43], and 
tyrosine kinase inhibitors [44], with mainly beneficial outcomes reported.  
 
1.3. Tumor metabolism: mechanisms and therapies 
 
1.3.1. The Warburg effect and beyond 
 
Early in the twentieth century, seminal findings by Otto Warburg demonstrated that rapidly 
proliferating cancerous cells exhibit a distinct metabolic phenotype compared to normal cells 
[45]. Transformed cells were found to ferment glucose to lactate independent of oxygen levels, 
an observation coined as the “Warburg effect” or “aerobic glycolysis” [45]. Paradoxically, 
cancer cells seemed to prefer a less efficient energy-generating process—glycolysis—over 
mitochondrial respiration. Warburg initially proposed that mitochondrial defects in cancer cells 
dictated their metabolic “possibilities”, however, it is now known that mitochondrial functions 
are not impaired in tumors, and that other underlying mechanisms may account for the observed 
metabolic reprogramming [45]. Furthermore, it is now widely accepted that the metabolic 
requirements of cancer cells exceed the need for ATP. In other words, for one parent cell to 
produce two daughter cells, cellular contents need to be duplicated, and thus in rapidly dividing 
cells, metabolism is tailored to shunt glucose into both biomass- and ATP-producing pathways 
[45].  
 
Over the years, investigations into this field have spawned a wealth of knowledge on the cancer 
type-specific metabolic aberrations, as well as possible contributors. For example, in prostate 
cells, malignancy-driven metabolic rewiring leads to inhibition of zinc accumulation, thereby 
relieving aconitase inhibition, and enabling complete citrate oxidation [46]. Moreover, in 
advanced castration-resistant prostate cancers, in addition to alterations in glucose metabolism, 
the disease is characterized by a lipogenic phenotype [47]. In breast cancers, studies have 
suggested that estrogen receptor (ER)-positive and –negative subtypes exhibit different 
metabolic phenotypes, where ER-positive cells have been described to adopt more typical 
Warburg metabolism, whereas ER-negative cells exhibit a higher dependence on glutamine 
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metabolism [48], a phenomenon known as “glutamine addiction”. Additionally, it has been 
shown that ER-negative breast cancer cells exhibit increased expression of the key de novo 
serine synthesis enzyme phosphoglycerate dehydrogenase (PHGDH) compared to ER-positive 
cells [49].  
 
1.3.2. Regulation of onco-metabolism by oncogenes and tumor suppressors 
 
While the consensus that cancer is a genetic disease remains, recent studies have argued that it 
is also a metabolic disease, since conditions such as obesity and insulin resistance are risk 
factors for cancer [50]. Recently, both schools of thought have been reconciled, with the 
demonstration that the genetic mutations in key tumor suppressors and proto-oncogenes that 
contribute to carcinogenesis also impact metabolic networks [51].  
 
1.3.2.1. p53 and metabolism 
 
Designated the “guardian of the genome”, p53’s canonical actions include cell cycle regulation 
and facilitation of DNA repair mechanisms, as well as regulation of apoptotic signaling [52]. 
The TP53 gene, encoding the p53 protein, is the most highly mutated gene in cancers [53], with 
mutations not only leading to loss of wild-type functions, but also generation of the so-called 
“mutant p53”, which is a pro-survival transcription factor [53]. Interestingly, the initial 
incorrect characterization of TP53 as an oncogene resulted from the cloning of a mutated 
version of the gene [53].  
  
Besides its well documented functions in maintaining genome integrity, recent studies have 
illustrated that p53 is a key metabolic regulator that works through influencing various arms of 
cellular energy production and utilization [54]. In tumor cells, wild-type p53 has been shown 
to dampen the Warburg effect and induce mitochondrial respiration, via modulating the 
expression of pivotal proteins, such as the glucose transporter 1 (GLUT1) and pyruvate 
dehydrogenase kinase (PDK) 2 [54], the enzyme responsible for phosphorylating the pyruvate 
dehydrogenase complex thus inhibiting its activity, which ultimately controls mitochondrial 
respiratory rate. p53 is also known to influence tricarboxylic acid (TCA) cycle anaplerosis, 
through inducing the expression of glutaminase (GLS) 2, which converts glutamine to 
glutamate, which can then be converted to alpha-ketoglutarate (α-KG) and incorporated into 
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the TCA cycle [54]. Furthermore, p53 has been shown to differentially modulate the pentose 
phosphate pathway (PPP) [54]. The nature of this regulation has been proposed to be subject to 
the degree of p53 activation, where activation in response to oxidative stress induces TIGAR 
(TP53-inducible glycolysis and apoptosis regulator), which leads to an increased flux through 
the PPP, essentially generating NADPH for oxidative defense [54]. TIGAR is a bisphosphatase 
that induces the conversion of fructose-2,6-bisphosphate, an allosteric activator of the rate-
limiting glycolytic enzyme phosphofructokinase, to fructose-6-phosphate [54]. In this regard, 
the molecule limits glycolytic flux and increases shunting of metabolites into the PPP. On the 
other hand, p53 is known to bind to the rate-limiting PPP enzyme glucose-6-phosphate 
dehydrogenase (G6PD) thus inhibiting its activity [54], leading to an inhibition of flux through 
this pathway and possibly reducing the levels of building blocks necessary to sustain tumor 
survival. Moreover, p53 also influences fatty acid metabolism, through reducing fatty acid 
biosynthesis and inducing beta-oxidation [54]. The former effect is partially achieved through 
reducing the expression of SREBP1c (sterol regulatory element-binding protein 1c), a 
transcription factor known to drive the expression of key enzymes in fatty acid biosynthesis, 
such as fatty acid synthase (FASN), ATP citrate lyase (ACLY), and acetyl CoA carboxylase 
(ACC) [54]. With regards to fatty acid beta-oxidation, p53 has been shown to induce carnitine 
acetyltransferases expression levels, which transport fatty acids to the mitochondria [54].        
 
1.3.2.2. PI3K/PTEN/Akt signaling  
 
The PI3K (phosphatidylinositol 3-kinase) pathway is a central regulator of metabolic networks 
in cancerous cells [55]. PI3K activation produces PIP3 (phosphatidylinositol-3,4,5-
triphosphate), a phospholipid which acts as an inducer of downstream targets, including Akt 
[55, 56]. This process is tightly regulated under normal conditions by the tumor suppressor 
PTEN (phosphatase and tensin homolog), which dephosphorylates PIP3, thereby inhibiting 
downstream pathways [55, 56]. In cancers however, activating and inhibiting mutations have 
been described in PI3K and PTEN, respectively, which deregulate the pathway, leading to the 
activation of Akt and triggering of metabolic transformation [55, 56]. Among the observed 
changes in cells’ metabolic profile upon activation of oncogenic Akt signaling is a potent 
induction in glycolysis, mediated by an increase in glucose uptake and expression of key 
glycolytic genes such as hexokinase II (HKII) and lactate dehydrogenase [57]. Additionally, 
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Akt activation induces mammalian target of rapamycin (mTOR) signaling [57], which also 
impacts cellular nutrient availability and utilization [58]. 
1.3.2.3. c-Myc and HIF1a 
 
c-Myc is an oncogene that is estimated to be overexpressed in 70% of cancers [59]. Similarly, 
HIF1a (hypoxia-inducible factor 1a) is known to be amplified in cancers due to intra-tumoral 
hypoxia [59]. Both moieties are transcription factors that regulate the expression of various 
transporters and enzymes involved in glucose metabolism [59]. Hyper-activation of both factors 
in transformed cells triggers a metabolic program, including induced glycolysis, which enables 
survival under hypoxic conditions [59].  
 
1.3.2.4. LKB1/AMPK/mTOR signaling 
  
AMP-activated protein kinase (AMPK) is a heterotrimeric complex that acts as an integral 
cellular metabolic sensor, responding to energetic stress (elevation in AMP:ATP ratio) through 
inhibiting and activating energy-depleting and –producing pathways, respectively [60]. In 
doing so, AMPK elevates ATP levels and prevents metabolic distress [60].  
 
The mechanism of AMPK activation involves binding of AMP to the complex’s gamma 
subunit, allosterically activating it, and enabling its further activation by its upstream kinase 
liver kinase B1 (LKB1), which phosphorylates threonine 172 on AMPK’s alpha-subunit [60]. 
LKB1 is a well characterized tumor suppressor, with mutations in the LKB1 gene implicated in 
different tumors, as well as in the genetic disorder Peutz-Jegher’s syndrome, in which sufferers 
have a predisposition to the development of various tumor types [61]. Moreover, besides 
activation of AMPK as a result of energetic stress, an increase in intracellular Ca2+ levels 
induces the activity of CAMKK2 (calcium/calmodulin-dependent kinase kinase 2), AMPK’s 
other activating kinase [60].    
 
AMPK’s metabolic effects are highly versatile, and include modulation of glucose uptake, 
glycolysis, gluconeogenesis, fatty acid metabolism, mitochondrial biogenesis, and finally, 
autophagy [60]. Additionally, AMPK activation leads to inhibition of the pro-survival mTOR 
pathway, thereby inhibiting protein synthesis [60]. In view of these effects, one is faced with 
the possibility that AMPK could acts as a tumor suppressor as well as an oncogene [62]. In 
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favor of the former is: i) the activation of this molecule by LKB1 (a tumor suppressor), ii) the 
resulting inhibition of mTOR, and finally, iii) phosphorylation and subsequently stabilization 
of tumor suppressor p53 by AMPK, leading to a metabolic cell cycle checkpoint. On the other 
hand, AMPK-mediated induction of energy-generating pathways, including glucose uptake, 
beta-oxidation of fatty acids, and autophagy, may enable cancer cells survive starvation.  
 
1.3.3. Therapeutic approaches for cancer metabolism 
 
Several reasons account for the clear emergence of cancer metabolism as a viable therapeutic 
target, including associations between aberrations in whole-body metabolism and cancer 
initiation and progression [50]. Furthermore, successful anti-cancer drugs that are currently in 
clinical use have either direct metabolic targets, such as 5-FU and methotrexate, which target 
thymidylate synthase and dihydrofolate reductase, respectively, or impact metabolic processes 
such as glucose uptake, which is the case of tyrosine kinase inhibitors [50]. The latter highlights 
the potential use of fluorodeoxyglucose-positron emission tomography as a predictor of 
response to chemotherapeutics that modulate signaling aberrations in cancer.   
 
However, multiple challenges remain in this field, for example, identifying metabolic targets 
that are safe to “drug” in cancer cells, while having minimal effects on normal or rapidly 
proliferating non-malignant cells, i.e. selectivity [50]. Noteworthy is that besides aerobic 
glycolysis and glutamine addition, which are known to be exhibited by different cancers, cancer 
type-specific metabolic aberrations have been reported, which may enable the (semi)-selective 
targeting of metabolism in cancer patients. For example, some cancers, such as prostate cancer 
and hepatocellular carcinoma, have been shown to be deficient in argininosuccinate synthase 
1, an important enzyme in de novo synthesis of the semi-essential amino acid arginine [63]. 
These tumors mainly rely on exogenous sources of arginine, making them “arginine 
auxotrophic” [63], and thus, depleting this extracellular supply, for example by using 
recombinant arginases [64], may impact tumor cell metabolism while having minimal effects 
on healthy cells’ metabolism.  
 
Moreover, cellular metabolism exhibits marked plasticity, which enables cells to 
bypass/overcome a metabolic insult induced by an anti-cancer drug targeting a particular 
metabolic enzyme, i.e. resistance [50]. In this regard, utilizing advanced technologies in 
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metabolic flux analyses will facilitate the tracing of these “escape routes” [50], and ultimately 
allow designing combinational strategies targeting different metabolic pathways 
simultaneously.   
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Table 1: List of promising novel and repurposed “metabolic” drugs that have demonstrated anti-tumor potential in cell-based and preclinical 
models. Such drugs limit either nutrient availability (e.g. recombinant human arginase 1) or utilization (e.g. metformin). 
Drug Target Rationale Experimental evidence References 
CBR-5884 PHGDH PHGDH, which catalyzes the first step in de 
novo serine synthesis, has been shown to be 
overexpressed in various cancers, making its 
inhibition a therapeutic strategy.  
This small molecule has been recently 
shown to be toxic to breast cancer cell 
lines more reliant on de novo serine 
synthesis, but not to those more dependent 
on exogenous sources.  
[65] 
CB-839 GLS Cancer cells are known to exhibit “glutamine 
addiction”, where studies have shown that 
glutamine is the second used nutrient in culture 
medium after glucose. GLS catalyzes the 
conversion of glutamine to glutamate, which 
can then contribute to TCA cycle anaplerosis. 
In preclinical studies, treatment of triple-
negative breast cancer models, as well as 
multiple myeloma xenografts with the 
drug yielded beneficial results. Clinical 
trials assessing the molecule’s efficacy in 
breast cancer and renal cell carcinoma 
patients are underway.    
[64, 66] 
rhArg1-PEG Arginine Some tumor cells are arginine auxotrophic, 
therefore, depleting extracellular/serum 
arginine by recombinant arginases is 
therapeutically advantageous.  
Treatment induces anti-tumor effects in 
in-vitro and in-vivo models of T-cell 
leukemia, and the molecule is currently in 
clinical trials of refractory lymphoma and 
leukemia. 
[63] 
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2-Deoxyglucose  Hexokinase Inhibition of glycolysis in cancer cells 
potentially leads to metabolic collapse and cell 
death. 
Tumor cells treated with 2-Deoxyglucose 
undergo apoptosis and/or growth arrest. 
Clinical data however illustrate that toxic 
effects are associated with therapy. 
[50] 
AG-221 Isocitrate 
dehydrogenase 
(IDH) 2 
IDH 1 and 2 genes are the most frequently 
mutated metabolic genes in tumors. These 
mutants give rise to the onco-metabolite R-2-
hydroxyglutarate, which alters cells’ 
epigenetic profile and hampers cellular 
differentiation. 
AG-221 has shown beneficial effects in 
ex-vivo and xenograft models of acute 
myeloid leukemia (AML), and is currently 
being tested in clinical trials against AML 
and solid tumors.  
[67-69] 
Metformin Mitochondrial 
complex I 
Inhibition of this target significantly reduces 
mitochondrial respiratory capacity, leading to 
substantial energetic stress and loss of cellular 
viability. 
Preclinical data demonstrate the potential 
utility of this molecule against different 
tumors, and several clinical trials are 
currently underway to investigate the 
efficacy of metformin against cancer.  
[70] 
Orlistat FASN FASN has been shown to be overexpressed in 
different cancers, and is associated with poor 
prognosis and reduced disease-free survival in 
patients. Overexpression of FASN has also 
been linked to chemoresistance. 
Orlistat has demonstrated anti-tumor 
potential in different cancer cell lines and 
preclinical models, most notably prostate 
cancer models.  
[71] 
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Etomoxir Carnitine 
palmitoyl-
transferase 1 
(CPT1) 
Fatty acid oxidation is an essential pathway for 
cancer cells to obtain ATP as well as NADPH 
for anabolic and redox processes. CPT1, which 
conjugates fatty acids with carnitine enabling 
their transport into the mitochondria for further 
metabolism, has been shown to be 
overexpressed in tumors, making it a potential 
drug target.   
Studies utilizing different human cancer 
cell lines, as well as a preclinical murine 
model of leukemia, demonstrated anti-
cancer effects with etomoxir treatment. 
However, hepatotoxicity was observed in 
patients treated with the drug in a clinical 
trial. 
[72-75] 
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1.4. Rationale and working hypothesis of the present research 
 
In light of the aforementioned data on the skeletal and supra-skeletal effects of calcitriol, I 
proposed that the molecule may also regulate energy production and utilization pathways in 
cancer cells. Although this theme had not been thoroughly investigated, few groups have 
reported on the ability of 1,25(OH)2D3 to influence cellular metabolism in different cell types, 
including transformed breast epithelial cells and dendritic cells [76, 77]. Furthermore, several 
pathways that are directly connected to nutrient metabolism and energetic stress have been 
shown to be impacted by 1,25(OH)2D3 treatment. For example, in both normal and transformed 
cells, calcitriol and its analogs have been shown to induce autophagy [78-82], a pro-survival 
pathway that is activated in response to starvation [83], via directly influencing autophagy 
genes [82], or through inducing AMPK signaling [78]. Additionally, 1,25(OH)2D3 has been 
shown to negatively regulate the expression of oncogenes implicated in tumor metabolism, 
namely c-Myc [27] and HIF1a [84]. Moreover, profound crosstalk between vitamin D and p53 
signaling has been reported [85, 86], indicating that putative metabolic effects could be 
executed through this channel. Finally, the key glucose-metabolizing gene—G6PD—as well as 
the regulator of glucose homeostasis, thioredoxin-interacting protein (TXNIP), have been 
proposed to be direct targets of 1,25(OH)2D3 [87, 88], which altogether served as the basis for 
the proposed research (Figure 2, modified from Abu el Maaty and Wölfl [89]). I focused on 
prostate and breast cancer cell lines in my work since studies have shown that 1,25(OH)2D3 
induces multi-faceted anti-cancer effects in both in-vitro and in-vivo models of both diseases 
[9]. Results of my investigations on prostate cancer cell lines have been recently published [90]. 
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Figure 2: Potential regulation of metabolic networks by 1,25(OH)2D3 through 
influencing different metabolism-related tumor-suppressors, oncogenes, and signaling 
molecules. Experimental evidence indicating calcitriol’s potential effects on energy 
metabolism include: i) the ability of calcitriol to reduce the expression of the oncogenes c-
Myc and HIF1a, which are known drivers of aerobic glycolysis, ii) activation of AMPK 
signaling and inhibition of the mTOR pathway by VDR activators, iii) crosstalk between 
VDR and p53 signaling, and iv) putative induction in G6PD and TXNIP expression by 
1,25(OH)2D3. Figure modified from Abu el Maaty and Wölfl [89]. 
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2. RESULTS 
2.1. Regulation of glucose-metabolizing pathways in prostate 
cancer cells by calcitriol. 
 
2.1.1. 1,25(OH)2D3 induces diverse changes in glucose metabolism of prostate 
cancer cells. 
 
The normal prostatic epithelium is known to exhibit a unique metabolic phenotype, 
characterized by a truncated TCA cycle due to an increase in intracellular Zn2+ levels, which 
inhibit the enzyme aconitase, leading to citrate accumulation [46]. Citrate is subsequently 
released in the seminal fluid to provide an energy source for sperm [91]. In malignant prostate 
cells, this phenotype is reversed, and citrate is further oxidized through the TCA cycle to yield 
reducing equivalents [46].  
 
To investigate the ability of 1,25(OH)2D3 to regulate glucose metabolism in prostate cancer 
cells, I utilized the biosensor chip system BIONAS 2500 to simultaneously measure, in real-
time, changes in glycolytic and respiratory rates, measured as extracellular acidification and 
oxygen consumption rates, respectively, as well as impedance, which provides information on 
the adherence/viability of cultured cells on the biosensor chip. To this end, I included in my 
study four prostate cancer cell lines of different androgen sensitivities: LNCaP and VCaP, 
representing androgen receptor (AR)-positive prostate cancer, as well as DU-145 and PC-3, 
representing AR-negative prostate cancer. Running medium (RM) not containing any treatment 
was first continuously introduced to the chips for 6h, after which either 1,25(OH)2D3- or 
dimethyl sulfoxide (DMSO)-treated RM was pumped for 72h, which was then followed by a 
recovery period of approximately 15h, in which cells were exposed to DMSO-treated RM. The 
three mentioned parameters were monitored throughout the course of the experiment. 
 
Interestingly, I observed significant reductions in glycolytic and respiratory rates in response to 
1,25(OH)2D3 treatment in all investigated cell lines, however, more potent changes were 
observed in the AR-positive cell lines LNCaP and VCaP (Figure 3).   
 
  RESULTS 
 19 
 
 
Focusing on LNCaP cells, I performed thorough analyses to investigate the diversity of 
1,25(OH)2D3’s metabolic effects. Since both extracellular acidification and oxygen 
consumption rates were clearly reduced by treatment in this cell line, I hypothesized that 
1,25(OH)2D3 influences metabolic aberrations that are observed in different cancer types, e.g. 
enhanced glucose uptake, as well as prostate-specific metabolic aberrations, e.g. the previously 
mentioned reversal of TCA cycle truncation. To address these possibilities, I first studied 
changes in glucose uptake of LNCaP cells in response to 1, 2, and 3 days of treatment with 
calcitriol, by measuring the concentration of glucose in the culture medium of both 
1,25(OH)2D3- and vehicle-treated cells, as well as by measuring the intracellular amount of 2-
NBDG (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose), a fluorescently 
labelled glucose analog, using fluorescence-activated cell sorting (FACS) analysis. I observed 
Figure 3: Real-time measurements of cellular bioenergetics in prostate cancer cell lines 
treated with 1,25(OH)2D3 (100 nM) using the Bionas 2500 biosensor chip system. 
Measurements obtained from 1,25(OH)2D3 -treated cells were normalized to those from 
DMSO-treated ones of the same cell line, however the data pertaining to all cell lines are 
presented together. The AR-positive cell lines LNCaP and VCaP appeared to be more 
responsive, in terms of altering their glycolytic capacity, to 1,25(OH)2D3 treatment, since their 
extracellular acidification rates were found to be reduced within the first day of treatment. 
Respiratory capacity of all cell lines, on the other hand, was found to be reduced in response 
to 1,25(OH)2D3, within the first day of treatment, with varying degrees. With regards to 
cellular viability, illustrated by impedance rate, only LNCaP cells were found to be impacted 
by 1,25(OH)2D3 treatment, with impedance rate found to be reduced starting second day of 
treatment. Results are representative of two biological replicates. Figure obtained from Abu 
el Maaty et al. [90]. 
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significantly higher levels of glucose in the medium of 1,25(OH)2D3-treated cells, and lower 
intracellular levels of 2-NBDG, across the investigated time course (Figure 4a,b), 
demonstrating a clear reduction in the uptake of glucose from the culture medium. I postulated 
that these effects may be coupled to a reduction in GLUT1 expression. This protein has been 
shown to be overexpressed in different tumors, and that this expression correlates with clinical 
outcome [92]. Indeed, I found that GLUT1 protein expression was significantly reduced in 
LNCaP cells after 72h of treatment with 1,25(OH)2D3 (Figure 4c,d).  
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To investigate whether 1,25(OH)2D3 influences the TCA cycle or not, levels of the cycle’s 
intermediates in LNCaP cells were analyzed using gas chromatography/mass spectrometry 
(GC/MS). A 72h treatment with 1,25(OH)2D3 resulted in a significant increase in 
citrate/isocitrate levels, and a decrease in other downstream intermediates (Figure 5), indicating 
a possible reversion to the metabolic phenotype of differentiated prostate cells. Although I did 
not thoroughly investigate this possibility, it is conceivable that 1,25(OH)2D3 truncates the TCA 
cycle in LNCaP cells by increasing intracellular levels of Zn2+. In support of this is the induced 
mRNA expression of the Zn2+ transporter SLC39A1 by calcitriol in LNCaP cells (data not 
shown).    
Figure 4: 1,25(OH)2D3 (100 nM) negatively influences glucose uptake in LNCaP cells. (A) 
Glucose uptake by DMSO- and 1,25(OH)2D3-treated LNCaP cells was evaluated using the 
fluorescently labeled glucose analog 2-NBDG coupled with FACS analysis, whereas levels of 
glucose in the medium were evaluated by the glucose oxidase (GOx) assay. The significant 
reduction observed in glucose uptake with 1,25(OH)2D3 treatment is complemented by a 
significant increase in glucose levels in the culture medium of such cells. Results of 
1,25(OH)2D3-treated cells of both experiments were normalized to their respective controls, 
and results are presented as fold change in the parameter investigated with treatment. Error 
bars ± standard deviation (SD) ; n=3. A two-tailed Student’s t-test was used to compare the 
results of DMSO- and 1,25(OH)2D3-treated cells, with ** and *** depicting p-values less than 
or equal to 0.01 and 0.001, respectively. (B) Representative histogram plot obtained from FACS 
analysis of glucose uptake. A clear reduction in fluorescence emission is observed with 
1,25(OH)2D3 treatment. Western blot (C) and associated densitometric analysis (D) of GLUT1 
protein levels in LNCaP cells in response to 72h of treatment with 1,25(OH)2D3. A significant 
reduction in protein levels are observed. Values below the blot are obtained from densitometric 
analysis of the presented bands. Figure obtained from Abu el Maaty et al. [90]. 
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Given the recognized role of the VDR as a transcription factor capable of regulating the 
expression of hundreds of genes [9], I postulated that significant changes in the mRNA 
expression of various metabolic genes would accompany, or partly explain the observed 
metabolic changes. I thus performed an mRNA expression analysis using RT-qPCR to 
investigate changes in the expression of genes encoding proteins involved in glucose, 
glutamine, and fatty acid metabolism. Surprisingly, the mRNA levels of all investigated 
metabolic genes were found to be reduced with 1,25(OH)2D3 treatment (Figure 6). I then aimed 
to confirm the down-regulation of the strongest hit—PDHK1 (pyruvate dehydrogenase kinase 
1)—by immunoblotting, and observed a significant reduction in the enzyme’s protein 
expression by treatment (Figure 7). 
 
 
Figure 5: Quantification of TCA cycle intermediates and anaplerosis-related amino acids in 
1,25(OH)2D3-treated LNCaP cells. 72h of treatment of LNCaP cells with 1,25(OH)2D3 (100 
nM) significantly increases citrate/isocitrate levels and decreases levels of downstream 
metabolites. Levels of select amino acids are also influenced by 1,25(OH)2D3 treatment. A two-
tailed Student’s t-test was used to compare the results of DMSO- and 1,25(OH)2D3-treated 
cells, with * and ** depicting p-values less than or equal to 0.05 and 0.01, respectively. Error 
bars ± SD ; n=3. Figure obtained from Abu el Maaty et al. [90]. 
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Figure 6: mRNA expression analysis of 
changes in metabolism-related genes in 
response to a 72h treatment with 
1,25(OH)2D3 (100 nM) in LNCaP cells. 
An overall downregulation in the various 
metabolic genes investigated is observed 
with treatment. Positive controls included 
are the vitamin D-catabolizing enzyme 
CYP24A1, as well as kallikrein-3/prostate 
specific antigen (KLK3), a differentiation 
marker that has been shown to be induced 
with 1,25(OH)2D3 treatment of prostate 
cancer cells. Relative expression is 
calculated using the ∆∆Ct method, with 
vinculin as the housekeeping gene (n=3). 
Figure obtained from Abu el Maaty et al. 
[90]. 
 
Figure 7: 1,25(OH)2D3 (100 nM) significantly reduces PDHK1 protein levels in LNCaP 
cells. Western blot analysis of PDHK1 levels in 72h DMSO- and 1,25(OH)2D3-treated 
LNCaP cells (left), and the associated densitometric analysis (right). Values below blots are 
obtained from densitometric analysis of the presented bands. A two-tailed Student’s t-test was 
used to compare the results of DMSO- and 1,25(OH)2D3-treated cells, with * depicting a p-
value of less than or equal to 0.05. Error bars ± SD ; n=3. Figure obtained from Abu el Maaty 
et al. [90]. 
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Finally, to investigate the influence of treatment on overall energy status across different time 
points, intracellular ATP levels were studied using a commercially available ATP assay kit. 
While ATP levels were found to be significantly reduced with calcitriol treatment after 24 and 
48h, they were not significantly affected by treatment in 72h (Figure 8). This is in line with the 
induction in mitochondrial mass and membrane potential observed after a 72h treatment with 
1,25(OH)2D3 (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
2.1.2. TXNIP expression is reduced by 1,25(OH)2D3, possibly due to an 
interplay between protein degradation and metabolic rewiring. 
 
Based on the observed changes in the metabolic phenotype of LNCaP cells in response to 
1,25(OH)2D3, I postulated that treatment also affects energy-related signaling molecules. As 
mentioned in the introduction section, several clues pointed towards the ability of calcitriol to 
Figure 8: Analysis of changes in mitochondrial biogenesis/activity in LNCaP cells in 
response to 24, 48, and 72h of treatment with 1,25(OH)2D3. Intracellular ATP levels were 
found to be significantly reduced after 24 and 48h of treatment with 1,25(OH)2D3 (100 nM), 
however, levels were normalized at the last time point, an observation coinciding with 
significantly elevated mitochondrial mass and membrane potential with 1,25(OH)2D3 
treatment. A two-tailed Student’s t-test was used to compare the results of DMSO- and 
1,25(OH)2D3-treated cells, with *, **, and *** depicting p-values less than or equal to 0.05, 
0.01, and 0.001, respectively. Error bars ± SD ; n=3. Figure obtained from Abu el Maaty et 
al. [90].  
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influence metabolic signaling networks. On one hand, the activity of the intracellular energy-
sensor AMPK has been shown to be induced by VDR activators [78]. On the other hand, the 
intracellular glucose-sensor TXNIP, has been initially characterized in AML (HL-60) cells as 
a gene that is induced by 1,25(OH)2D3 treatment, thus termed the vitamin D3 upregulated 
protein 1 (VDUP1) [88].  
 
AMPK is a heterotrimeric complex, consisting of beta and gamma regulatory subunits, as well 
as an alpha catalytic subunit [60]. In response to energetic stress—an increase in AMP:ATP 
ratio—AMPK inhibits and activates energy-consuming and –producing pathways, respectively 
[60]. TXNIP, however, is known to be an integral part of cellular glucose sensing. An increase 
in intracellular levels of glycolytic intermediates is sensed by the transcriptional heterodimer 
MondoA/Max-like protein X (MLX), leading to its nuclear translocation and subsequent 
binding to carbohydrate response elements on the TXNIP promoter, inducing its expression 
[93]. TXNIP subsequently limits glucose uptake through reducing the expression and/or 
limiting the plasma membrane availability of GLUT1 [94]. Wu et al. [94] have demonstrated 
that TXNIP is also a component of AMPK signaling, one that is phosphorylated by AMPK, 
leading to its degradation, and ultimately, increased glucose uptake. 
 
Considering this, I studied AMPK signaling activity, using phosphorylated ACC (S79) as a 
marker of the pathway’s activation, as well as the expression levels of TXNIP, in response to 
1,25(OH)2D3 treatment, using immunoblotting. After 24, 48, and 72h of treatment, AMPK 
signaling and TXNIP expression were found to be consistently induced and reduced with 
treatment, respectively (Figure 9 and Figure 10).  
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The latter observation was striking, given the long-assumed connection between the vitamin 
and the protein. However, noteworthy is that the canonical regulation of TXNIP expression by 
1,25(OH)2D3 has only been observed on the mRNA level in HL-60 cells, and analysis of mouse 
VDUP1 gene promoter did not reveal the presence of VDRE [95]. Additionally, I observed a 
mild, yet significant induction in TXNIP mRNA levels in response to 1,25(OH)2D3 (Figure 6). 
To determine whether the canonical regulation occurs at earlier time points, I treated LNCaP 
cells with 1,25(OH)2D3 for 1, 3, 6, and 12h, and investigated TXNIP levels using 
immunoblotting. Not only was a clear induction in TXNIP protein level absent, but a reduction 
Figure 9: 1,25(OH)2D3 (100 nM) 
activates AMPK signaling in 
LNCaP cells. pACC (S79) was 
found to be induced with treated 
across the investigated time points. 
Values below blots are obtained 
from densitometric analysis of the 
presented bands. Figure obtained 
from Abu el Maaty et al. [90].  
 
Figure 10: 1,25(OH)2D3 consistently 
reduces TXNIP expression in LNCaP cells. 
Western blot analysis of TXNIP reveals a 
profound reduction in protein expression 
with 1,25(OH)2D3 (100 nM) treatment at the 
different time points investigated. Values 
below blots are obtained from densitometric 
analysis of the corresponding bands. Figure 
obtained from Abu el Maaty et al. [90].  
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in its expression level was also observed after 3 and 6h of treatment, and a marked decrease 
was observed after 12h of treatment (Figure 11).  
 
 
 
 
 
   
 
 
To investigate this finding further, I hypothesized that the observed induction in AMPK led to 
TXNIP degradation. To address this possibility, I first sought to confirm TXNIP degradation 
by 1,25(OH)2D3. LNCaP cells were therefore treated with either DMSO or calcitriol for 66h, 
after which proteasomal and lysosomal inhibitors, MG-132 and leupeptin, respectively, were 
added to the conditioned medium for an additional 6h. Furthermore, as a positive control of 
TXNIP regulation, 2-Deoxyglucose, a non-metabolizable glucose analog, was similarly added 
to the conditioned medium 24h prior to the end of the intended treatment period with DMSO 
or 1,25(OH)2D3 (72h). 2-Deoxyglucose enters cells and is phosphorylated by hexokinase, but 
does not undergo further glycolytic steps. An accumulation of 2-Deoxyglucose-6-phosphate 
mimics elevated levels of glycolytic intermediates, which triggers the translocation of 
MondoA/MLX into the nucleus, thus inducing TXNIP expression. In the present setting, the 
possibility that the reduction in TXNIP levels is due to treatment-induced metabolic 
changes/reduced glycolytic flux, could be addressed using this experimental approach, since 
TXNIP would be potentially rescued by 2-Deoxyglucose in such case. All employed treatments 
were found to rescue TXNIP levels in the presence of 1,25(OH)2D3 (Figure 12).    
 
With regards to the involvement of AMPK signaling in mediating calcitriol’s effects on TXNIP 
degradation, I speculated that activation of this signaling pathway by 1,25(OH)2D3 might be 
Figure 11: Canonical regulation of TXNIP by 1,25(OH)2D3 is not observed in short time 
points. Western blot analysis of TXNIP levels in DMSO- and 1,25(OH)2D3 (100 nM)-treated 
LNCaP cells reveals a reduction in expression with treatment in as early as 3h. Values below 
blots are obtained from densitometric analysis of the corresponding bands. Figure obtained 
from Abu el Maaty et al. [90].  
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due to treatment-induced energetic stress and/or increased intracellular Ca2+ levels. The latter 
leads to AMPK activation through activating its upstream kinase CAMKK2 [60]. To investigate 
the role of these pathways, I treated LNCaP cells with an AMPK inhibitor (compound C) [60], 
or a CAMKK2 inhibitor (STO-609) [96], in the presence of either DMSO or 1,25(OH)2D3. 
LNCaP cells were therefore treated for 48h with a vehicle or calcitriol, to ensure reduction in 
TXNIP levels, after which the different inhibitors were added to the conditioned medium for 
an additional 24h. Interestingly, STO-609, but not compound C, rescued TXNIP expression in 
the presence of 1,25(OH)2D3 (Figure 12).  
 
 
In addition to the described effects of 1,25(OH)2D3 treatment on metabolism-related signaling 
molecules, previous studies have shown that the oncogene c-Myc is downregulated by calcitriol 
in prostate cancer cells [97]. As previously mentioned, c-Myc is implicated in the metabolic 
Figure 12: TXNIP is degraded in response to 1,25(OH)2D3 treatment, possibly through 
activation of AMPK signaling. (Left) Reduction of TXNIP protein levels with 1,25(OH)2D3 
(100 nM) treatment is rescued by the proteasomal and lysosomal inhibitors, MG-132 (5 µM) 
and leupeptin (20 µM), respectively, as well as by the positive control 2-Deoxyglucose (10 
mM). Cells were initially treated with either DMSO or 1,25(OH)2D3 for 66h, after which the 
inhibitors were added to the conditioned medium for an additional 6h. 2-Deoxyglucose was 
similarly added to the conditioned medium of cells, 48h after the initial treatment, for an 
additional 24h. (Right) The small molecule CAMKK2 inhibitor STO-609 (20 µM), but not 
compound C (5 µM), rescues TXNIP protein levels in the presence of 1,25(OH)2D3. The 
molecules were added to the conditioned medium of 48h treated cells, for an additional 24h. 
Values below blots are obtained from densitometric analysis of the corresponding bands. 
Figure obtained from Abu el Maaty et al. [90].  
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reprogramming observed in tumors, through promoting the glycolytic pathway [59]. 
Additionally, Myc has been shown to either cooperate or compete with MondoA in mediating 
metabolic effects in different tumors [98]. For example, in triple-negative breast cancer, c-Myc 
has been shown to drive glycolysis through reducing TXNIP (a MondoA target) expression in 
breast cancer cells [99]. On the other hand, in neuroblastoma, N-Myc and MondoA were 
described as cooperatively regulating glutamine metabolism [100]. Although such relationship 
has not been described in prostate cancer, I aimed to investigate the possibility that the overall 
reduction in glucose metabolism with 1,25(OH)2D3 treatment in LNCaP cells is at least partly 
mediated through its reduction of c-Myc levels, which consequently leads to a reduction in 
TXNIP expression. To test this hypothesis, I first aimed to confirm the downregulation of c-
Myc levels in LNCaP cells by calcitriol, which were indeed found to be reduced after 72h of 
treatment (Figure 13). I then added the Myc-Max hetero-dimerization and transactivation 
inhibitor 10058-F4 [101], to the conditioned medium of LNCaP cells treated for 48h with either 
DMSO or 1,25(OH)2D3, for an additional 24h. Similar to calcitriol’s effects, 10058-F4 
markedly reduced TXNIP expression in LNCaP cells (Figure 13), demonstrating that c-Myc 
inhibition decreases TXNIP levels through direct and/or indirect mechanisms. Directly, for 
example, through recruiting transcription repressing complexes to the TXNIP promoter, and 
indirectly, through reducing glycolytic flux thereby decreasing the levels of TXNIP-inducing 
glycolytic intermediates.  
 
 
Figure 13: c-Myc potentially contributes to the regulation of TXNIP by 1,25(OH)2D3 in LNCaP 
cells.  (Left) Western blot analysis illustrating the reduction of c-Myc levels in LNCaP cells after 
72h of treatment with 1,25(OH)2D3 (100 nM). (Right) The small molecule c-Myc inhibitor 10058-
F4 (20 µM), added to the medium of 48h DMSO- or 1,25(OH)2D3-treated cells for an additional 
24h, was found to markedly decrease TXNIP protein expression in LNCaP cells independent of 
1,25(OH)2D3. Values below blots are obtained from densitometric analysis of the corresponding 
bands. Figure obtained from Abu el Maaty et al. [90]. 
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2.1.3. Metabolic regulation by 1,25(OH)2D3 in LNCaP cells is largely androgen 
receptor-independent. 
 
Given the diversity and potency of calcitriol’s metabolism-regulating activities in the AR-
positive cell line LNCaP, I questioned the importance of the AR in mediating or facilitating 
these effects. The AR has been recently shown to influence glucose metabolizing pathways in 
prostate cancer cells [102], and extensive crosstalk between the AR and the VDR has been 
described [31, 103]. Firstly, I confirmed results of earlier reports demonstrating significant 
induction in AR expression in LNCaP cells with 1,25(OH)2D3 treatment (Figure 14) [28, 29].  
 
 
 
To examine the role of the AR in calcitriol’s regulation of TXNIP expression, I transiently 
knocked-down AR levels in LNCaP cells and treated them with either DMSO or 1,25(OH)2D3. 
Results demonstrate a reduction in TXNIP expression in LNCaP cells by treatment independent 
of AR expression levels (Figure 15).   
Figure 14: AR levels are consistently induced in LNCaP cells with 1,25(OH)2D3 treatment. 
Western blot analysis of AR levels in LNCaP cells in response 1,25(OH)2D3 (100 nM) over a 
time course (left), as well as after 72h of treatment (middle). (Right) A significant increase in 
AR protein levels after 72h of 1,25(OH)2D3 treatment is illustrated by densitometric analysis of 
the corresponding bands (middle blot). A two-tailed Student’s t-test was used to compare the 
AR protein levels in DMSO- and 1,25(OH)2D3-treated cells, and ** depicts a p-value of less 
than or equal to 0.01. Error bars ± SD ; n=3. Figure obtained from Abu el Maaty et al. [90]. 
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To further investigate the role of the AR in the observed metabolic changes, increasing 
concentrations of the AR agonist and antagonist, testosterone and casodex, respectively, were 
added to the conditioned medium of LNCaP cells treated for 48h with either DMSO or 
1,25(OH)2D3, for an additional 24h, after which both TXNIP protein expression and glucose 
uptake levels were evaluated. Testosterone treatment led to a minor increase in TXNIP protein 
level, an effect that was accompanied by a reduction in glucose uptake (Figure 16). However, 
in the presence of calcitriol, testosterone treatment did not alter the reduction in TXNIP 
expression (Figure 16). On the other hand, while calcitriol induces AR expression and casodex 
is an AR antagonist, similar effects on TXNIP expression were observed, where a single high 
dose of casodex (100 µM) was found to deplete TXNIP levels (Figure 16). Noteworthy is that 
this dose did not appear to alter glucose uptake of LNCaP cells (Figure 16).  
Figure 15: Knocking-down AR levels in LNCaP 
cells does not influence regulation of TXNIP by 
1,25(OH)2D3 (100 nM). Western blot analysis of 
TXNIP levels in DMSO- and 1,25(OH)2D3-treated 
LNCaP cells, transfected with anti-AR siRNA or a 
negative control (NC). Reduction in TXNIP levels 
after 24h of treatment is independent of AR levels. 
Values below the blot are obtained from 
densitometric analysis of the corresponding 
bands. Figure obtained from Abu el Maaty et al. 
[90].  
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Since 1,25(OH)2D3 treatment was also found to transcriptionally regulate metabolic genes, I 
investigated whether AR stimulation or inhibition led to similar effects on the mRNA 
expression of select genes. The same treatment plan for the AR modulators as described in the 
previous section was employed, however a single dose of each molecule was used. While 
1,25(OH)2D3-mediated transcriptional regulation of PDHK1 was mimicked by both 
testosterone and casodex, regulation of GLUT1 by the AR modulators was in opposing fashion 
to 1,25(OH)2D3’s effect (Figure 17). Moreover, the reduction of GLUT1, PDHA1 (pyruvate 
Figure 16: Pharmacological modulators of the AR do not influence 1,25(OH)2D3’s effects 
on TXNIP or glucose uptake in LNCaP cells. Increasing concentrations of testosterone (10-
40 nM) or casodex (25-100 µM), added to the conditioned medium of 48h DMSO- or 
1,25(OH)2D3 (100 nM)-treated cells, for an additional 24h, do not diminish the negative 
regulation of TXNIP protein levels (top) or glucose uptake (bottom) by 1,25(OH)2D3. Values 
below blots are obtained from densitometric analysis of the corresponding bands. A two-tailed 
Student’s t-test was used to compare the results of DMSO-treated cells and the different 
conditions, with * and ** depicting p-values less than or equal to 0.05 and 0.01, respectively. 
Statistical significance between the mono-treatments and the combination treatments is 
depicted by a dagger. Error bars ± SD ; n=2. Figure obtained from Abu el Maaty et al. [90].  
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dehydrogenase E1 component alpha 1 subunit), and PDHK1 mRNA expression by 
1,25(OH)2D3 was not observed in cells co-treated with casodex. Therefore, taking all the data 
together, I concluded that calcitriol’s metabolic effects are largely AR-independent.  
 
 
 
 
 
 
 
Figure 17: Effects of 1,25(OH)2D3 on the mRNA expression of metabolic genes in LNCaP 
cells is partially AR-dependent. While the effect of testosterone (40 nM) or casodex (100 µM) 
on PDHK1 mRNA levels mimicked that of 1,25(OH)2D3 (100 nM), reduction in GLUT1 and 
PDHA1 mRNA levels in response to 1,25(OH)2D3 appeared to be blocked in the presence of 
casodex. A two-tailed Student’s t-test was used to compare the results of DMSO-treated cells 
and the different conditions, with *, ** and *** depicting p-values less than or equal to 0.05, 
0.01 and 0.001, respectively. Statistical significance between the different conditions and 
1,25(OH)2D3 is depicted by a dagger Error bars ± SD ; n=2. Figure obtained from Abu el 
Maaty et al. [90]. 
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2.2. 1,25(OH)2D3 impacts energy-generating and glucose-sensing 
networks in breast cancer cells. 
 
2.2.1. Calcitriol treatment differentially regulates metabolic networks in 
luminal and basal breast cancer cells. 
 
Encouraged by the demonstrated ability of 1,25(OH)2D3 to induce diverse metabolic changes 
in prostate cancer cells, I wondered if similar effects could also be observed in experimental 
models of another endocrine-related cancer. As previously highlighted, studies have illustrated 
that 1,25(OH)2D3 possesses multi-faceted anti-tumor effects in breast cancer models, including 
regulation of the cell cycle, apoptosis, and estrogen signaling [9]. I therefore sought to 
investigate the ability of the molecule to regulate metabolic processes in breast cancer cell lines 
representing different molecular subtypes. Using MCF-7 and MDA-MB-231 cells as 
representative models for luminal and basal breast cancers, respectively, I studied changes in 
glycolytic and respiratory rates using the BIONAS 2500 biosensor chip system mentioned in 
the previous section. In MCF-7 cells, 1,25(OH)2D3 was found to gradually induce glycolytic 
rate over the course of three days, but did not impact respiratory rate in the same time frame 
(Figure 18). In contrast to these observations, respiratory, but not glycolytic rate in MDA-MB-
231 cells was found to be reduced with 1,25(OH)2D3 treatment (Figure 18). 
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To get a clearer view of 1,25(OH)2D3-mediated metabolic changes in the different cell lines, 
GC/MS-based metabolomics was performed to quantify TCA cycle intermediates as well as 
levels of select amino acids in response to treatment. I observed differential regulation of levels 
of TCA cycle metabolites by calcitriol in the different cell lines (Figure 19). In MCF-7 cells, 
1,25(OH)2D3 treatment clearly reduced citrate levels as well as levels of downstream 
intermediates (Figure 19). In MDA-MB-231 cells however, the treatment led to a marked 
increase in citrate and α-KG levels (Figure 19). Strikingly, I observed a profound induction in 
intracellular serine levels in MCF-7 cells with treatment (Figure 19). This observation was of 
interest since numerous recent studies have focused on the importance of this non-essential 
amino acid to cancer cell survival [104].  
 
 
 
 
Figure 18: Simultaneous, real-time measurements of glycolytic, respiratory, and impedance 
rates in breast cancer cell lines treated with 1,25(OH)2D3 (100 nM). In MCF-7 cells, 
1,25(OH)2D3 treatment appeared to induce glycolytic rate, but not respiratory capacity. On 
the other hand, respiratory, but not glycolytic rate in MDA-MB-231 cells, was found to be 
reduced with 1,25(OH)2D3. Measurements obtained from 1,25(OH)2D3-treated cells were 
normalized to those from DMSO-treated ones of the same cell line, however the data pertaining 
to all cell lines are presented together. Data are representative of two biological replicates. 
Figure 19: GC/MS-based quantification of 
TCA cycle metabolites and amino acids in 
breast cancer cells treated with 1,25(OH)2D3 
(100 nM). In MCF-7 cells, levels of citrate as 
well as other downstream TCA cycle 
metabolites were reduced in response to a 72h 
treatment with 1,25(OH)2D3. In MDA-MB-231 
cells, however, an accumulation in citrate and 
α-KG is observed. A profound increase in 
intracellular serine levels in 1,25(OH)2D3-
treated MCF-7 cells is also observed. Results 
are the average of two biological replicates.  
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Additionally, I postulated that calcitriol treatment may majorly regulate the expression of 
various metabolic genes in breast cancer cells in a manner similar to that observed in LNCaP 
cells. I thus aimed to evaluate the expression of not only genes related to glucose, glutamine 
and fatty acid metabolism, but also those involved in p53- and autophagy-signaling, since the 
two investigated cell lines exhibit different p53 variations—wild-type (MCF-7) and mutant 
(MDA-MB-231)—as well as because recent reports demonstrated the ability of VDR activators 
to trigger autophagy in breast tumor cells [82, 105]. Contrary to the findings in LNCaP cells, 
the mRNA expression levels of most investigated genes were not significantly reduced with 
calcitriol treatment (Figure 20). Furthermore, the mRNA expression of the G6PD gene was 
found to be clearly induced by treatment in both cell lines (Figure 20). This enzyme is 
responsible for catalyzing the first reaction of the PPP, which provides cells with precursors for 
biosynthetic pathways as well as NADPH for anti-oxidant defense [106, 107]. Furthermore, 
studies have illustrated that G6PD is overexpressed in different cancer types [106], making it a 
potential oncogene.  
 
 
 
 
 
Figure 20: Analysis of mRNA 
expression of metabolic genes in 
breast cancer cells treated for 72h 
with 1,25(OH)2D3 (100 nM). While 
most genes were found to be mildly 
regulated by treatment in both cell 
lines, the G6PD gene was found to be 
induced by 1,25(OH)2D3 in MCF-7 
and MDA-MB-231 cells. Relative 
expression was calculated using the 
∆∆Ct method, with vinculin as the 
housekeeping gene. Data presented 
are the average of two biological 
replicates. 
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To assess the overall energy status of breast cancer cells, the previously mentioned ATP assay 
was utilized to quantify intracellular ATP levels in response to 24, 48, and 72h of treatment 
with calcitriol. While treatment led to a significant reduction in ATP levels in MCF-7 cells at 
the latest investigated time point, the opposite effect was observed for MDA-MB-231 cells 
(Figure 21).  
 
 
 
 
 
 
 
 
 
 
 
2.2.2. 1,25(OH)2D3 induces TXNIP degradation in MCF-7 cells. 
 
Following the characterization of 1,25(OH)2D3-induced metabolic changes in breast cancer 
cells, I investigated the regulation of AMPK signaling and TXNIP expression by treatment, 
employing the same strategy adopted for LNCaP cells. While 72h of treatment with calcitriol 
led to a clear induction in AMPK activity and a significant reduction in TXNIP levels in MCF-
7 cells, minor effects were observed in MDA-MB-231 cells (Figure 22).  
Figure 21: Assessment of overall energy levels in DMSO- and 1,25(OH)2D3 (100 nM)-treated 
breast cancer cells. Luminescence values, correlating with cellular ATP levels, were normalized 
to cellular protein content. A two-tailed Student’s t-test was used to compare the results of 
DMSO- and 1,25(OH)2D3-treated cells, with *, ** and *** depicting p-values less than or equal 
to 0.05, 0.01 and 0.001, respectively. Error bars ± SD ; n=3.   
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Motivated by similar non-canonical regulation in prostate cancer cells, I aimed to characterize 
the nature of TXNIP regulation by 1,25(OH)2D3 in MCF-7 cells. I started by employing a 
thorough time course, comprising both short and long time points (1-72h), and studying the 
1,25(OH)2D3-mediated regulation of TXNIP mRNA and protein expression. I observed an 
initial induction in TXNIP mRNA levels at the early time points (1-3h), however, this was 
largely ablated at the later time points (6-72h) (Figure 23). Protein levels on the other hand 
appeared to be unaffected by treatment at early time points, but a clear reduction in expression 
levels was observed starting at 12h (Figure 23).  
 
 
Figure 22: Western blot analysis of changes in TXNIP levels and AMPK signaling 
activation in breast cancer cells in response to 72h of 1,25(OH)2D3 (100 nM) treatment. 
Levels of TXNIP and pACC (S79) appeared to be differentially regulated by 1,25(OH)2D3 in 
MCF-7 cells (left) and MDA-MB-231 (right). 
Figure 23: Time-dependent evaluation of changes in TXNIP mRNA (left) and protein (right) 
levels in MCF-7 cells in response to 1,25(OH)2D3 (100 nM) treatment. Relative expression 
was calculated using the ∆∆Ct method, with vinculin as the housekeeping gene. The lines in 
the middle of the floating bars represent the mean of two biological replicates, and the upper 
and lower ends of the bars represent the highest and lowest values, respectively. 
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Since TXNIP is involved in both glucose and redox homeostasis [93, 108, 109], I assessed 
glucose uptake and intracellular ROS levels in 1,25(OH)2D3-treated MCF-7 cells. While 
intracellular ROS levels were found to be insignificantly affected by treatment in the 
investigated time points, glucose uptake was found to be reduced after 24 but not 72h of 
treatment (Figure 24).  
 
 
 
 
 
 
 
 
 
I then posited that 1,25(OH)2D3-mediated metabolic reprogramming might have reduced the 
levels of TXNIP-inducing glycolytic intermediates—thereby hampering the initial rise in 
TXNIP mRNA levels—and/or led to TXNIP degradation via AMPK induction. Therefore, I 
devised an experiment in which MG-132 or 2-Deoxyglucose are added to the conditioned 
medium of MCF-7 cells, treated for 72h with either DMSO or 1,25(OH)2D3, 2 and 24h before 
the 72h-treatment period was over, respectively. While I observed complete rescuing of TXNIP 
expression in response to 1,25(OH)2D3 treatment by 2-Deoxyglucose, MG-132 only partially 
rescued the molecule’s expression (Figure 25). To further confirm this, I treated MCF-7 cells 
with 1,25(OH)2D3 for 72h, during which MG-132 was added to the culture medium at different 
time points prior to the end of the 1,25(OH)2D3 treatment period. The presence of calcitriol was 
found to delay TXNIP rescuing by MG-132 (Figure 25). 
 
Figure 24: Changes in glucose uptake and intracellular ROS levels in response to 
treatment of MCF-7 cells with 1,25(OH)2D3 (100 nM). 24h of treatment was found to 
significantly reduce glucose uptake, an effect that was not observed after 72h. Intracellular 
ROS levels were found to be unaltered by calcitriol in the investigated time points. A two-
tailed Student’s t-test was used to compare the results of DMSO- and 1,25(OH)2D3-treated 
cells, with ** depicting p-values less than or equal to 0.01. Error bars ± SD ; n=3.   
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While TXNIP degradation as a result of AMPK activation remained a possibility, I proposed 
that treatment might have also regulated the expression/activity of TXNIP-degrading 
machinery. Recent studies, reviewed thoroughly by Álvarez-Díaz et al. [110], illustrated the 
ability of vitamin D to modulate the expression of diverse protein degradation players. Since 
Zhang et al. [111] have recently shown that ITCH, an E3 ubiquitin ligase, is responsible for 
marking TXNIP for proteasomal degradation, I tested whether 1,25(OH)2D3 leads to TXNIP 
degradation through inducing ITCH expression. Indeed, treatment was found to significantly 
induce both ITCH mRNA and protein levels (Figure 26). To assess the possible extent of this 
induction on TXNIP degradation, I treated MCF-7 cells with the de novo protein synthesis 
inhibitor cycloheximide (CHX), both in the presence and absence of 1,25(OH)2D3. Similar to 
the MG-132 experiment described above, CHX was added to the conditioned medium of cells 
at different time points before the end of the 72h treatment period with either DMSO or 
calcitriol. While CHX treatment led to a time-dependent reduction in TXNIP half-life in 
DMSO-treated cells, rescuing of TXNIP levels was observed in 1,25(OH)2D3-treated cells at 
the latest CHX time point (Figure 26), highlighting the possibility that induction in the 
expression of ITCH—or other TXNIP-degrading machinery—contributed to TXNIP 
degradation by treatment.  
 
Figure 25: 1,25(OH)2D3 (100 nM) induces TXNIP degradation in MCF-7 cells. (Left) MG-
132 (5 µM) added to the culture medium of DMSO- or 1,25(OH)2D3-treated MCF-7 cells 2h 
prior to the end of the treatment period (72h), only partially rescues the reduction in TXNIP 
protein levels by 1,25(OH)2D3. (Right) MG-132, added to the medium of cells treated with 
either DMSO or 1,25(OH)2D3 for different periods before the end of the initial treatment 
(72h), induces delayed rescuing of TXNIP protein expression in 1,25(OH)2D3-treated cells. 
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To investigate the involvement of AMPK signaling in TXNIP regulation by 1,25(OH)2D3, 
AMPKα1 was knocked-down in MCF-7 cells using siRNA. Cells were subsequently treated 
with either DMSO or 1,25(OH)2D3 for 24 and 72h, after which TXNIP expression was assessed 
by immunoblotting. Knocking-down AMPKα1 levels appeared not to influence the reduction 
in TXNIP expression by 1,25(OH)2D3 at either time point (Figure 27).  
 
 
 
 
 
 
 
Figure 26: 1,25(OH)2D3 induces ITCH expression in MCF-7 cells. 72h of treatment with 
1,25(OH)2D3 (100 nM) induces ITCH mRNA (left) and protein (middle) levels. ITCH mRNA 
relative expression is calculated using ∆∆Ct method with vinculin as the housekeeping gene. 
A two-tailed Student’s t-test was used to compare the results of DMSO- and 1,25(OH)2D3-
treated cells, with * depicting p-values less than or equal to 0.05. Error bars ± SD ; n=2. 
(Right) CHX (10 µM), added to the medium of DMSO- or 1,25(OH)2D3-treated cells at 
different time points before the end of the 72h treatment period, reduces TXNIP protein half-
life and rescues TXNIP protein levels in DMSO- and 1,25(OH)2D3-treated cells, respectively, 
in a time-dependent manner.  
Figure 27: Reduction of TXNIP protein expression by 1,25(OH)2D3 (100 nM) in MCF-7 
cells is AMPK-independent. 24 (left) and 72h (right) of treatment with 1,25(OH)2D3 
negatively regulate TXNIP levels in cells transfected with either anti-AMPKα1 siRNA or NC. 
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To further confirm the lack of involvement of AMPK signaling in 1,25(OH)2D3’s regulation of 
TXNIP expression, I sought to limit the possibility of the treatment activating this pathway by 
increasing intracellular Ca2+ levels. I therefore treated MCF-7 cells for 24h with either the low-
calcemic VDR activator calcipotriol [35], or 1,25(OH)2D3, the latter in the presence and 
absence of the cell permeable Ca2+ chelator bis-(o-aminophenoxy)-ethane-N,N,N,N'-tetraacetic 
acid/tetra(acetoxymethyl)-ester (BAPTA-AM) [78], added to the condition medium for the last 
2h of treatment. Calcipotriol treatment elicited similar effects on TXNIP expression as 
1,25(OH)2D3, whereas the addition of BAPTA-AM to 1,25(OH)2D3-treated MCF-7 cells did 
not attenuate TXNIP’s regulation by treatment (Figure 28). 
 
 
 
 
 
 
 
2.2.3. Metabolic adaptation to 1,25(OH)2D3 possibly contributes to TXNIP 
regulation. 
 
I then decided to revisit the possibility that certain metabolic changes provoked by treatment 
contributed to the observed reduction in TXNIP expression. Based on the observation that the 
increase in TXNIP mRNA expression was found to be transient and short-lived, I speculated 
that certain metabolic changes reduced the levels of glycolytic metabolites capable of inducing 
the nuclear translocation of MondoA/MLX. Based on the previous findings that MCF-7 cells 
treated for 72h with calcitriol exhibit higher mRNA expression of G6PD (Figure 20), as well 
as increased serine levels compared to DMSO-treated cells (Figure 19), I posited that two 
Figure 28: 1,25(OH)2D3’s regulation of 
TXNIP expression in MCF-7 cells is 
independent of its calcemic effects. Treatment 
of cells for 24h with calcipotriol (100 nM) 
reduces TXNIP proteins levels in a manner 
similar to that observed with 1,25(OH)2D3 (100 
nM). Addition of BAPTA-AM (20 µM) to the 
conditioned medium of DMSO- or 
1,25(OH)2D3-treated cells, 2h before the end of 
the treatment period, does not alter 
1,25(OH)2D3’s regulation of TXNIP.  
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glycolytic side branches—namely the PPP and the serine synthesis pathway (SSP)—might be 
induced by calcitriol, essentially diverting metabolites away from the glycolytic pathway. 
Additionally, the increased extracellular acidification rate observed in MCF-7 cells with 
calcitriol treatment (Figure 18) might also be indicative of reduced levels of glycolytic 
metabolites.   
 
I therefore decided to focus on calcitriol’s regulation of G6PD expression, as well as lactate 
production, as potential contributors to the observed TXNIP regulation. In this regard, I first 
aimed to confirm the induction in G6PD expression by 1,25(OH)2D3 on both the protein and 
activity levels, as well as elucidate the time point at which mRNA levels are first induced. 
G6PD mRNA levels were found to be induced by treatment in as early as 6h (Figure 29), i.e. 
the time point at which the ablation in TXNIP mRNA induction by calcitriol was first observed 
(Figure 23). Additionally, a significant induction in G6PD protein expression was observed 
after 72h of treatment (Figure 29). Complementary data was obtained for the enzyme’s activity, 
which was found to be strongly induced after 72h of treatment (Figure 29).  
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Increasing concentrations of the non-competitive G6PD inhibitor dehydroepiandrosterone 
(DHEA) [112] were then added to the conditioned medium of MCF-7 cells treated for 48h with 
calcitriol or a vehicle, for an additional 24h. Independent of 1,25(OH)2D3, DHEA treatment 
reduced TXNIP expression in a dose-dependent manner (Figure 30). A similar experimental 
setup was repeated using the lactate dehydrogenase inhibitor Na oxamate [113]. In the absence 
of calcitriol, Na oxamate was found to minorly modulate TXNIP levels, whereas in the presence 
of calcitriol, a dose-dependent decrease in expression levels was observed (Figure 30). In view 
of these results, I propose that inhibiting the flow of metabolites through a particular pathway, 
e.g. through the PPP using DHEA, or glycolysis using Na oxamate, prompts metabolites to be 
shunted into other “activated” pathways in 1,25(OH)2D3 treated cells. In other words, while 
inhibiting the PPP in 1,25(OH)2D3-treated cells might prevent the flux of metabolites through 
this pathway, other pathways induced by 1,25(OH)2D3 treatment may provide free channels—
for example glycolysis—for these metabolites to enter.  
 
Figure 29: 1,25(OH)2D3 (100 nM) induces G6PD expression and activity in MCF-7 cells. 
(A) G6PD mRNA levels are induced with 1,25(OH)2D3 in a time-dependent manner. Relative 
expression was calculated using the ∆∆Ct method, with vinculin as the housekeeping gene. 
Upper, lower, and middle lines of the floating bars represent the highest, lowest, and the 
average value of two biological replicates, respectively. (B,C) Western blot and associated 
densitometric analysis of G6PD levels in 72h DMSO- and 1,25(OH)2D3-treated MCF-7 cells. 
A two-tailed Student’s t-test was used to compare the results of DMSO- and 1,25(OH)2D3-
treated cells, with *** depicting p-values less than or equal to 0.001. (D) Kinetic 
measurements of the increase in absorbance associated with the reduction of NADP+ to 
NADPH by G6PD in DMSO- and 1,25(OH)2D3-treated MCF-7 crude lysates. The rate of 
reduction was found to be significantly higher with 1,25(OH)2D3 treatment indicating 
increased enzymatic activity of G6PD. 
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2.2.4. Pharmacological targeting of metabolic “weak points” in 1,25(OH)2D3-
treated breast cancer cells. 
 
Although the anti-tumor effects of calcitriol in MCF-7 cells have been reported in many 
publications [114, 115], a number of observations described above question the therapeutic 
efficacy of calcitriol in luminal breast cancers. To further clarify, several metabolic changes 
triggered with treatment appear to be survival-promoting in nature. For example, induction in 
lactate production and intracellular serine levels (onco-metabolites), as well as G6PD 
expression (a potential oncogene) by 1,25(OH)2D3 treatment in MCF-7 cells are seemingly 
undesirable “metabolic side-effects” that could hamper the molecule’s therapeutic potential. I 
postulated that this metabolic adaptation to calcitriol treatment is either a resistance mechanism 
that enables cells to withstand the molecule’s anti-tumor effects, or simply an unwanted vitamin 
D effect, similar to treatment-induced hypercalcemia. Either way, targeting these potential 
metabolic “weak points” may enhance calcitriol’s therapeutic efficacy.  
 
Figure 30: Inhibition of G6PD or lactate dehydrogenase does not rescue TXNIP protein 
expression in 1,25(OH)2D3-treated cells. Western blot analysis of TXNIP expression in MCF-
7 cells treated with increasing concentrations of DHEA (25-100 µM) or Na Oxamate (25-100 
mM), added to the conditioned medium of cells treated for 48h with either DMSO or 
1,25(OH)2D3 (100 nM), for an additional 24h. Results illustrate a dose-dependent decrease in 
TXNIP levels independent and dependent of 1,25(OH)2D3, in the case of DHEA and Na 
Oxamate, respectively. 
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To address this issue, I first treated MCF-7 cells for 72h with increasing concentrations of the 
G6PD inhibitor DHEA, in the presence and absence of calcitriol, and assessed the proliferation 
of cells. A combination of both molecules was found to induce more profound anti-proliferative 
effects compared to mono-treatment with DHEA (Figure 31).  
 
 
 
 
 
 
 
 
 
 
With regards to the increased serine levels observed with treatment, I hypothesized that 
1,25(OH)2D3 reduces the cellular uptake of the amino acid, prompting an increase in its de novo 
synthesis. Supporting this possibility is the reduction in SLC1A5 (a serine transporter) 
expression by calcitriol in transformed breast epithelial cells reported by Zhou et al. [116]. 
CBR-5884 is a novel small molecule inhibitor of the SSP enzyme PHGDH [65]. This molecule 
has been shown to impact the survival of cancer cells relying more on de novo serine synthesis 
than uptake [65]. Thus, in the postulated setting of reduced serine uptake with 1,25(OH)2D3 and 
the compensatory induction in the SSP, calcitriol treatment would prime MCF-7 cells to be 
more susceptible to CBR-5884’s anti-tumor effects. Indeed, treating MCF-7 cells for 72h with 
a combination of 1,25(OH)2D3 and various concentrations of CBR-5884 led to more potent 
anti-proliferative effects compared to CBR-5884 alone (Figure 32).  
Figure 31: Sulforhodamine B (SRB) assay evaluating the influence of 1,25(OH)2D3 on the 
anti-proliferative effects of DHEA in MCF-7 cells. DHEA treatment (72h) was found to 
clearly reduce proliferation rate in a dose-dependent manner, an effect that was augmented 
in the presence of 1,25(OH)2D3 (100 nM). Results obtained from the different treatments are 
normalized to those of DMSO-treated cells. A two-tailed Student’s t-test was used to compare 
the results of mono- and co-treatments, with ** and *** depicting p-values less than or equal 
to 0.01 and 0.001, respectively. Error bars ± SD ; n=2. 
C
el
lu
la
r p
ro
lif
er
at
io
n 
(%
 o
f c
on
tr
ol
) 
DHEA (µM) 
  RESULTS 
 47 
 
 
    
 
 
 
 
 
 
To investigate whether the observed calcitriol-mediated serine accumulation—through 
contributing to the folate cycle and thymidine synthesis—may hamper the efficacy of anti-
metabolites such as 5-FU, MCF-7 cells were treated for 72h with increasing concentrations of 
5-FU, in the presence of either DMSO or 1,25(OH)2D3, and cellular proliferation was evaluated. 
The presence of calcitriol consistently led to a significant reduction in cellular proliferation with 
5-FU, compared to cells treated with 5-FU alone (Figure 33).    
 
 
 
 
 
 
 
 
 
 
Figure 32: 1,25(OH)2D3 (100 nM) markedly potentiates the anti-proliferative effects of 
CBR-5884 in MCF-7 cells. SRB assay reveals a significant reduction in the proliferation of 
MCF-7 cells treated for 72h with a combination of 1,25(OH)2D3 and CBR-5884, compared 
to cells treated with the latter alone. Results obtained from the different treatments are 
normalized to those of DMSO-treated cells. A two-tailed Student’s t-test was used to compare 
the results of mono- and co-treatments, with ** and *** depicting p-values less than or equal 
to 0.01 and 0.001, respectively. Error bars ± SD ; n=2.  
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2.3. Regulation of the putative vitamin D target gene—TXNIP—by 
calcitriol.  
 
2.3.1. 1,25(OH)2D3 treatment differentially regulates TXNIP levels in diverse 
cancer cell lines. 
 
Results of the above-mentioned investigations elucidated the possibility that in cancers, 
calcitriol treatment may not universally lead to an upregulation in the expression of the putative 
tumor suppressor TXNIP. In LNCaP and MCF-7 cells, 1,25(OH)2D3 was found to substantially 
reduce TXNIP protein levels, whereas in MDA-MB-231 cells, treatment does not profoundly 
alter its expression levels (Figure 10 and Figure 22). In view of this, I aimed to address the 
question of whether TXNIP really is a vitamin D upregulated protein, and whether the canonical 
regulation is observed in cancer cell lines besides HL-60 cells. Noteworthy is that this 
regulation has only so far been described in HL-60 cells [88, 117], and that promoter analysis 
did not identify VDRE in the mouse VDUP1 [95]. On the other hand, another report identified 
putative VDRE in the TXNIP promoter using in-silico transcription factor binding prediction 
software, however the functionality of this site has not been tested [118]. My investigations into 
this theme have been recently published [119]. 
 
 
 
Figure 33: Observed potentiation of 5-FU’s anti-proliferative effects in MCF-7 cells upon 
co-treatment with 1,25(OH)2D3 (100 nM). 72h of treatment with the 5-FU-1,25(OH)2D3 
combination exhibits increased efficacy compared to treatment with 5-FU alone, as illustrated 
by the SRB assay data. Results obtained from the different treatments are normalized to those 
of DMSO-treated cells. A two-tailed Student’s t-test was used to compare the results of mono- 
and co-treatments, with *, **, and *** depicting p-values less than or equal to 0.05, 0.01, and 
0.001, respectively. Error bars ± SD ; n=2. 
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I thus first aimed to screen the regulation of this gene on the protein level in response to a 72h 
treatment with calcitriol in different cell lines of diverse tissue origins. Cell lines derived from 
hematological (HL-60, Jurkat, U937), liver (HepG2, HLE, SK-HEP-1), breast (MDA-MB-231, 
MCF-7), prostate (LNCaP, DU145, PC3), pancreatic (AsPC-1, BxPC-3, PC3), and colorectal 
(HCT116, HT-29) cancers were included in the study, and changes in TXNIP protein 
expression in response to treatment were evaluated by immunoblotting.  
 
The different cell lines exhibited varying degrees of basal TXNIP expression, with certain cell 
lines exhibiting very low or undetectable protein levels (Figure 34). In cell lines with seemingly 
silenced TXNIP expression, such as Jurkat, DU145, and PC3 cells, calcitriol treatment did not 
induce its expression (Figure 34). On the other hand, in cell lines expressing detectable TXNIP 
protein levels, its expression was found to be either induced, reduced, or unchanged with 
1,25(OH)2D3 treatment, demonstrating that the canonical increase in TXNIP protein level by 
calcitriol is not present in all cell lines (Figure 34). 
 
  RESULTS 
 50 
 
In view of these findings, I decided to take a closer look at 1,25(OH)2D3’s regulation of TXNIP 
expression in the cell line in which it was first discovered, HL-60. Since the original report by 
Chen and Deluca only described the regulation on the mRNA level [88], I sought to replicate 
their findings, as well as add additional late time points, to get a clearer picture of whether this 
induction in mRNA expression is transient or sustained. I therefore treated HL-60 cells with 
calcitriol for 1, 3, 6, 24, 72, and 96h, and analyzed TXNIP mRNA levels using RT-qPCR. 
Interestingly, while the expected induction in mRNA levels was observed with treatment in the 
early time points (up to 24h of treatment), the induction in mRNA levels was not only hampered 
at the later time points, but also mildly reduced with treatment (Figure 35).  
 
 
 
 
 
 
 
 
 
Figure 34: Differential regulation of TXNIP expression by 1,25(OH)2D3 (100 nM) in cancer 
cell lines of various tissue origins. Western blot analysis of TXNIP expression in cells treated 
for 72h with 1,25(OH)2D3. Canonical induction with treatment is only observed in 
hematological cancer cell lines (U937 and HL-60), whereas non-canonical regulation is 
observed in LNCaP, SK-HEP-1, BxPC-3, and MCF-7. Lack of regulation is also observed in 
cell lines with and without basal TXNIP expression, such as HT-29 and HCT116, respectively. 
Figure obtained from Abu el Maaty et al. [119].    
Figure 35: TXNIP mRNA levels are only transiently induced in 1,25(OH)2D3-treated HL-
60 cells. The increase in TXNIP mRNA expression with calcitriol (100 nM) treatment is 
observed at earlier time points (≤ 24h), and is succeeded by an apparent reduction at later 
time points. Relative expression was calculated using the ∆∆Ct method, with vinculin as the 
housekeeping gene. Upper, lower, and middle lines of the floating bars represent the highest, 
lowest, and the average value of two biological replicates, respectively. Figure obtained from 
Abu el Maaty et al. [119].    
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I then studied the regulation of TXNIP protein expression across similar time points. A mild 
increase in TXNIP protein expression was observed after 24h of treatment with calcitriol, 
whereas a more profound induction was observed after 96h. Additionally, basal TXNIP 
expression displayed treatment-independent temporal fluctuations (Figure 36). I speculated 
that at the latest investigated time point (96h), the observed increase in TXNIP protein levels 
with 1,25(OH)2D3 stemmed from the reduced availability of glucose in the culture medium in 
vehicle-treated cells, leading to a reduction in intracellular glycolytic intermediates and 
consequently basal TXNIP expression. 
 
 
To investigate the possibility that depletion in glucose levels contributed to the reduced basal 
TXNIP expression at the last time point, I measured the concentration of glucose in the medium 
of HL-60 cells treated with either DMSO or 1,25(OH)2D3, over a 4-day time course. Although 
the level of glucose in the culture medium of DMSO-treated cells was significantly lower 
compared to that of 1,25(OH)2D3-treated cells—possibly due to inhibition of cellular 
proliferation with the latter—levels were not found to be depleted even at the latest time point 
(Figure 37), which indicates that the observed temporal fluctuations in TXNIP protein 
Figure 36: Increase in TXNIP protein levels with 1,25(OH)2D3 is only observed in HL-60 
cells at the latest investigated time point. Western blot analysis of time-dependent regulation 
of TXNIP expression by 1,25(OH)2D3 (100 nM). While TXNIP protein expression was found 
to exhibit temporal fluctuations independent of 1,25(OH)2D3, a clear induction in the protein’s 
level is observed after 96h of treatment. 2-Deoxyglucose (10 mM) and MG-132 (5 µM) were 
included as positive controls, added to the culture medium of cells 24 and 6h prior to the end 
of the treatment period (72h) with either DMSO or 1,25(OH)2D3, respectively. Figure obtained 
from Abu el Maaty et al. [119].       
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expression reflect the engagement of TXNIP in normal glucose homeostasis rather than critical 
reduction in glucose availability.  
 
 
 
 
 
 
Furthermore, I studied the potential functional consequences of TXNIP expression, by 
examining changes in intracellular ROS and glucose uptake with calcitriol treatment, across a 
time course spanning short and long time points. Intracellular ROS levels were found to be 
insignificantly influenced by calcitriol at most investigated time points, except at 96h, in which 
levels were found to be markedly induced with treatment (Figure 38). Glucose uptake, on the 
other hand, was found to be significantly induced and reduced with treatment, after 6 and 72h 
(Figure 38), respectively, highlighting the possible contribution of intracellular 
glucose/glycolytic metabolites to TXNIP mRNA regulation by 1,25(OH)2D3 (Figure 35).    
 
 
Figure 37: Analysis of changes in glucose 
concentrations in the culture medium of HL-60 
cells treated with either DMSO or 1,25(OH)2D3 
over time. The time-dependent decrease in 
glucose levels in the medium of vehicle-treated 
cells is not observed with 1,25(OH)2D3 (100 nM) 
treatment, possibly due to the reduction in 
cellular proliferation.  Glucose levels are not 
depleted in either experimental condition at the 
latest time point. Error bars ± SD ; n=3. Figure 
obtained from Abu el Maaty et al. [119].     
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2.3.2. 1,25(OH)2D3 increases TXNIP expression in HL-60 cells through 
transcriptional induction and protein stabilization. 
 
Although looking at glucose concentrations in the culture medium did not point towards TXNIP 
protein stabilization by calcitriol per se, the observed minor reduction in TXNIP mRNA levels 
after 96h of treatment was indicative of the lack/minimal contribution of 
transcriptional/translational induction to the clear increase in protein levels with 1,25(OH)2D3 
at this time point. To confirm this, HL-60 cells were treated with either DMSO or calcitriol for 
96h, and CHX was added to the conditioned medium at different time points before the end of 
the 96h treatment period. In DMSO-treated cells, CHX treatment led to a profound decrease in 
TXNIP protein half-life in a time-dependent manner (Figure 39). On the other hand, in 
1,25(OH)2D3-treated cells, CHX treatments did not significantly decrease TXNIP protein levels 
(Figure 39), demonstrating the lack of involvement of de novo protein synthesis in TXNIP 
protein induction by a 96h calcitriol treatment. 
Figure 38: Changes in intracellular ROS levels and glucose uptake in HL-60 cells in 
response to 1,25(OH)2D3 (100 nM). While differential regulation of glucose uptake was 
observed with treatment at the different time points, a significant induction in intracellular 
ROS levels with 1,25(OH)2D3 was only observed after 96h of treatment. A two-tailed Student’s 
t-test was used to compared the results of DMSO- and 1,25(OH)2D3-treated cells, with * and 
** depicting p-values less than or equal to 0.05 and 0.01, respectively. Error bars ± SD ; n=3. 
Figure obtained from Abu el Maaty et al. [119].    
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I then repeated the same experimental setup for a time point at which TXNIP mRNA levels 
were induced with treatment (24h). The addition of CHX was found to reduce TXNIP protein 
half-life in both DMSO- and 1,25(OH)2D3-treated HL-60 cells (Figure 40), demonstrating the 
differential modes of TXNIP regulation by treatment (transcriptional/translational induction in 
24h, and protein stabilization in 96h).   
 
 
 
Figure 39: CHX (10 µM) reduces TXNIP protein half-life in 96h DMSO-, but not 
1,25(OH)2D3 (100 nM)-treated HL-60 cells. (Left) Representative western blot analysis of the 
time-dependent decrease in TXNIP protein expression with CHX, observed in cells treated 
with DMSO, but not in those treated with 1,25(OH)2D3. CHX treatments were performed in 
the culture medium of treated HL-60 cells at multiple time points before the end of the 
DMSO/1,25(OH)2D3 treatment period (96h). (Right) Densitometric analysis of two similar 
western blot experiments. A two-tailed Student’s t-test was used to compare the results of 
DMSO-treated cells and the different conditions. *, **, and *** depict p-values less than or 
equal to 0.05, 0.01, and 0.001, respectively. A dagger depicts significance between mono- and 
co-treatment. Error bars ± standard error of the mean (SEM). Figure obtained from Abu el 
Maaty et al. [119].     
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Subsequently, I postulated that similar to the observations in MCF-7 cells, 1,25(OH)2D3 may 
impact TXNIP protein stability in HL-60 cells through regulating ITCH expression. Although 
24 and 96h of treatment with calcitriol significantly reduced ITCH mRNA levels in HL-60 
cells, protein expression was unchanged with treatment (Figure 41).  
Figure 40: CHX (10 µM) reduces TXNIP half-life in HL-60 cells treated for 24h with DMSO 
or 1,25(OH)2D3 (100 nM). Representative western blot (left) and densitometric analysis (right) 
of two similar experiments. CHX treatments were performed in the culture medium of treated 
HL-60 cells at multiple time points before the end of the DMSO/1,25(OH)2D3 treatment period 
(24h). A two-tailed Student’s t-test was used to compared the results of DMSO-treated cells 
and the different conditions. * and ** depict p-values less than or equal to 0.05 and 0.01, 
respectively. Error bars ± SEM. Figure obtained from Abu el Maaty et al. [119].     
 
Figure 41: 1,25(OH)2D3 (100 nM) regulates ITCH mRNA but not protein expression in HL-
60 cells. (Left) 24 and 96h of treatment with 1,25(OH)2D3 reduce ITCH mRNA levels in HL-60 
cells. Relative expression was calculated using the ∆∆Ct method with vinculin as the 
housekeeping gene. A two-tailed Student’s t-test was used to compare the results of DMSO- and 
calcitriol-treated cells. * depicts p-values less than or equal to 0.05. Error bars ± SD ; n=2. 
1,25(OH)2D3 treatment, however, does not regulate ITCH protein levels in HL-60 cells after 24 
(middle) or 96h (right). Figure obtained from Abu el Maaty et al. [119].    
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2.3.3. Regulation of TXNIP expression by 1,25(OH)2D3 in HL-60 cells possibly 
involves glucose-sensing networks, but is not a consequence of glucose 
metabolism reprogramming. 
 
Given the well-defined role of the glucose-sensing transcription heterodimer MondoA/MLX in 
regulating TXNIP expression [93], I hypothesized that regulation by 1,25(OH)2D3 may be 
dependent on the functionality of this pathway. I therefore cultured HL-60 cells in glucose-free 
medium and investigated TXNIP mRNA expression after 24 and 96h of 1,25(OH)2D3 
treatment. Indeed, the induction and reduction in the mRNA expression of TXNIP observed in 
HL-60 cells after 24 and 96h of calcitriol treatment, respectively, were diminished in the 
absence of glucose (Figure 42). However, the vitamin D catabolizing enzyme CYP24A1 was 
found to be induced by treatment independent of glucose levels (Figure 42).  
 
 
 
 
 
 
 
 
 
Furthermore, I investigated the regulation of TXNIP protein levels by 1,25(OH)2D3 in HL-60 
cells cultured in either full medium or medium lacking glucose. Under glucose-free conditions, 
TXNIP protein levels were found to be strongly depleted, and their levels unaltered by 
Figure 42: Regulation of TXNIP mRNA expression in HL-60 cells by 1,25(OH)2D3 (100 
nM) is glucose-dependent. Bi-directional regulation of TXNIP mRNA expression by 
1,25(OH)2D3 is not present in cells cultured in glucose-free medium. However, the regulation 
of CYP24A1 mRNA expression in HL-60 cells by 96h of treatment with 1,25(OH)2D3 was 
found to be independent of glucose levels in the medium. Relative expression is calculated 
using the ∆∆Ct method with vinculin as the housekeeping gene. A two-tailed Student’s t-test 
was used to compare the results of the different conditions. * and ** depict p-values less than 
or equal to 0.05 and 0.01, respectively. n.s.=non-significant. Error bars ± SD ; n=2. Figure 
obtained from Abu el Maaty et al. [119].    
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1,25(OH)2D3 treatment (Figure 43). Similarly, in the presence of the glucose transporter 
inhibitor phloretin [120], calcitriol was incapable of inducing TXNIP protein levels (Figure 
43), which altogether highlight the necessity of both glucose in the medium, and a functioning 
glucose transport system, for 1,25(OH)2D3 to induce TXNIP expression. Additionally, the 
induction in intracellular ROS levels after 96h of treatment of HL-60 cells with 1,25(OH)2D3 
was also diminished in the absence of glucose (Figure 44). However, the anti-proliferative 
effects of 1,25(OH)2D3 were observed in HL-60 cells cultured in full medium and glucose-free 
medium (Figure 45). 
 
 
 
 
 
Figure 43: Regulation of TXNIP protein expression in HL-60 cells by 1,25(OH)2D3 depends 
on glucose-availability, and a functioning glucose transport system. (Left) Western blot analysis 
of TXNIP levels in cells treated with either DMSO or 1,25(OH)2D3 (100 nM), cultured in either 
glucose-free or full medium. (Right) A single high concentration of phloretin (200 µM), added to 
culture medium containing either DMSO or 1,25(OH)2D3, at multiple time points before the end 
of the 24h treatment period, inhibits 1,25(OH)2D3’s regulation of TXNIP. Figure obtained from 
Abu el Maaty et al. [119].    
Figure 44: Induction of intracellular ROS by 1,25(OH)2D3 
in HL-60 cells is glucose-dependent. 96h of treatment with 
1,25(OH)2D3 (100 nM) induces ROS in HL-60 cells cultured 
in full medium, but not in those cultured in glucose-free 
medium. Significance between the different experimental 
conditions is calculated using a two-tailed Student’s t-test, 
with ** depicting a p-value less than or equal to 0.01.  Error 
bars ± SD ; n=3. Figure obtained from Abu el Maaty et al. 
[119].    
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Since I have previously observed that TXNIP regulation by 1,25(OH)2D3 in prostate and breast 
cancer cells is linked to metabolic reprogramming, I sought to investigate the metabolic effects 
calcitriol induces in HL-60 cells. Real-time measurements of culture medium pH and levels of 
dissolved oxygen, reflecting glycolytic and respiratory rates, respectively, were performed in 
response to 1,25(OH)2D3 treatment over a course of 4 days. Calcitriol treatment appeared not 
to induce major differences in the metabolic parameters investigated (Figure 46). 
Figure 46: 1,25(OH)2D3 (100 nM) does not markedly influence glucose metabolism in HL-
60 cells. Continuous monitoring of changes in the pH of the culture medium and levels of 
dissolved oxygen demonstrate lack/minimal influence of 1,25(OH)2D3 on either parameter. 
Differences in the measurements observed between DMSO and 1,25(OH)2D3 treatments in the 
fourth day are possibly attributed to the effect of the latter on cellular proliferation. Controls 
used for oxygen and pH measurements include metformin (2 mM) and 2-Deoxyglucose (10 mM), 
respectively, as well as culture medium not containing cells (RPMI: Roswell Park Memorial 
Institute). Figure obtained from Abu el Maaty et al. [119].    
Figure 45: 1,25(OH)2D3 (100 nM) reduces 
proliferation of HL-60 cells cultured in full 
medium or glucose-free medium. A two-tailed 
Student’s t-test was used to compare the results 
of the different conditions at the latest time point, 
with * and *** depicting p-values less than or 
equal to 0.05 and 0.001, respectively. Error bars 
± SD ; n=3. Figure obtained from Abu el Maaty 
et al. [119].    
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Despite this, calcitriol was found to induce significant alterations in the overall energy status of 
HL-60 cells, assessed using an ATP assay (Figure 47). In 24h, 1,25(OH)2D3 significantly 
reduced cellular ATP levels, whereas in 48 and 72h, levels were significantly elevated with 
treatment (Figure 47). However, activation of the metabolic stress-related signaling pathway 
AMPK, was neither observed after 24 nor 96h of treatment (Figure 47), which altogether 
illustrate that treatment-induced metabolic rewiring is an unlikely contributor to TXNIP 
regulation by 1,25(OH)2D3 in HL-60 cells. 
 
Figure 47: 1,25(OH)2D3 (100 nM) treatment does not induce AMPK signaling in HL-60 cells. 
Although 1,25(OH)2D3 was found to differentially alter cellular ATP levels across different time 
points (left), induction in ACC (S79) phosphorylation was neither observed after 24 (middle) nor 
96h (right) of treatment. ATP measurements were normalized to cell count, and are presented as 
fold change with 1,25(OH)2D3 treatment. Statistical significance is assessed using a two-tailed 
Student’s t-test, with ** and *** depicting p-values less than or equal to 0.01 and 0.001, 
respectively.  Error bars ± SD ; n=3. Figure obtained from Abu el Maaty et al. [119].    
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3. DISCUSSION 
 
Prior to the completion of the work presented in this thesis, the appreciated anti-cancer roles of 
1,25(OH)2D3 and its analogues were diverse, however, did not include modulation of energy 
metabolism. The results presented in this thesis illustrate previously uncharacterized effects of 
calcitriol on distinct metabolic networks in different cancer models. Additionally, data 
challenge the previously unquestioned notion of TXNIP being a vitamin D upregulated protein. 
In the following subsections, I discuss in depth the newly recognized role of vitamin D as a 
potent modulator of onco-metabolism, the potential underlying causes and consequences of 
TXNIP’s non-canonical regulation by 1,25(OH)2D3, and finally, provide an outlook on the 
future of vitamin D-based chemotherapy, in view of the new findings. 
 
3.1. 1,25(OH)2D3-mediated regulation of metabolic networks in 
tumor cells. 
 
Based on the results described in this thesis, calcitriol clearly modulates glucose metabolizing 
pathways in endocrine-related cancers, namely in prostate and breast cancer cell lines (Figure 
3 and Figure 18). I demonstrate that 1,25(OH)2D3 regulates the expression of various genes 
implicated in tumoral glucose metabolism, such as GLUT1 (Figure 4), PDHK1 (Figure 7), and 
G6PD (Figure 29), as well as energy-related signaling molecules, including AMPK and TXNIP 
(Figure 9, Figure 10, Figure 22). 
 
Although these 1,25(OH)2D3-mediated metabolic effects are less studied compared to the anti-
proliferative and pro-apoptotic ones, I argue that such investigations shed light on ways to 
enhance the molecule’s anti-tumor potential, and that a better understanding of calcitriol’s 
effect on energy metabolism would enable the harnessing of its beneficial effects, while 
suppressing the potentially counter-therapeutic ones. For example, in MCF-7 cells, 
1,25(OH)2D3 triggers versatile metabolic events that typically support tumor growth, including 
induction of G6PD expression and activity (Figure 29), accumulation of serine (Figure 19), 
and enhanced lactate production (Figure 18). Even though proliferation of MCF-7 cells was 
found to be markedly inhibited by 1,25(OH)2D3 (data not shown), it is possible that a subset of 
these metabolic responses represents a resistance mechanism adopted by cells. Thus, inhibition 
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of such escape routes through genetic or pharmacological means may potentiate calcitriol’s 
anti-cancer effects. For instance, I demonstrate that pharmacological inhibition, using CBR-
5884, of the SSP, which is proposed to be induced in 1,25(OH)2D3-treated MCF-7 cells, 
enhances the overall treatment’s efficacy (Figure 32). Similarly, based on their findings that 
calcitriol induces autophagy—which plays both tumor inhibiting and promoting roles—in 
luminal breast cancer cells, Tavera-Mendoza et al. [82] illustrated that co-treating mice grafted 
with MCF-7, or MCF-7 cells in-vitro, with calcitriol and an inhibitor of autophagosome 
degradation (chloroquine or hydroxychloroquine), leads to a toxic accumulation of 
autophagosomes, and ultimately, potentiation of calcitriol’s anti-tumor effects. Such approach 
may improve the efficacy of VDR activators in other cancer types, since vitamin D compounds 
have been shown to induce autophagy in different cancer models [79, 80]. 
 
In addition to inducing metabolic changes in tumor cells, calcitriol may elicit similar effects in 
stromal cells, in view of recent findings illustrating beneficial effects of VDR activation in 
cancer-associated fibroblasts [41, 121]. For example, Sherman et al. [41] recently showed that 
calcipotriol induces profound genetic changes in pancreatic stellate cells—the most prevalent 
fibroblastic type of cells in the pancreatic tumor microenvironment—which induce their 
conversion from “activated” to “quiescent”. This effect enhances the tumoral delivery of 
gemcitabine, leading to an improved survival in mice receiving both calcipotriol and 
gemcitabine, compared to animals receiving gemcitabine alone [41]. A different study by 
Ferrer-Mayorga et al. [121] demonstrated that increased VDR expression in fibroblasts of the 
tumor stroma positively correlates with overall survival in patients with colorectal cancer. The 
authors also illustrated that treatment of cancer-associated fibroblasts with 1,25(OH)2D3 
induces a gene signature that correlates with improved overall- as well as disease free-survival 
in patients [121]. Since metabolic crosstalk has been demonstrated between tumor and stromal 
cells [122], it would be interesting to investigate the potential role of vitamin D signaling in 
influencing this symbiosis.    
 
Besides reprogramming glucose metabolism in tumor cells, the influence of calcitriol on fatty 
acid and amino acid metabolism remains a possibility. Based on the data obtained from initial 
metabolic screens on prostate and breast cancer cells, 1,25(OH)2D3 treatment modulates overall 
levels of different amino acids (Figure 5 and Figure 19), as well as the mRNA expression of 
glutamine- and fatty acid-metabolizing enzymes (Figure 6). In transformed breast epithelial 
cells, studies have illustrated that 1,25(OH)2D3 treatment reduces glutamine uptake and lipid 
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accumulation, due to a reduction in SLC1A5 (a vital glutamine transporter) expression [116], 
and fatty acid synthesis [123], respectively.  
 
Despite accumulating evidence highlighting vitamin D’s extra-skeletal activities, the molecule 
is still mainly viewed as a regulator of calcium homeostasis. Nonetheless, it is possible that 
such classical role may underscore new roles in transformed cells, both oncogenic and tumor 
suppressing. In other words, aberrations in calcium signaling are becoming increasingly linked 
to tumorigenesis, where studies have illustrated increased expression of various calcium 
channels, such as TRPV6 (transient receptor potential cation channel, subfamily V, member 6), 
in breast and prostate cancer [124]. Interestingly, the TRPV6 gene, whose expression correlates 
with prostate cancer severity [125], is a direct target of the VDR [8]. Moreover, in LNCaP cells, 
TRPV6 has been linked to enhanced survival and resistance to apoptosis, and with regards to 
calcitriol, paradoxically, has been shown to be induced by treatment, and to confer resistance 
to apoptotic induction by calcitriol as well [126]. Regarding regulation of metabolic processes, 
overexpression of various calcium channels in cancers may lead to diverse signaling events, 
such as activation of AMPK, through activating its upstream kinase CAMKK2, potentially 
leading to autophagy induction. Such model may explain the constitutive activation of AMPK, 
observed by Park et al. [127] in prostate cancer cell lines and human tissues. Similar to the 
counter-therapeutic induction of TRPV6 in LNCaP cells reported by Lehen’kyi et al. [126], 
activation of AMPK signaling by 1,25(OH)2D3 in the same cell line illustrated in this thesis, 
may dampen the molecule’s therapeutic potential/efficacy, by inducing pro-survival pathways, 
namely autophagy. Although I observed metabolic reprogramming and a reduction in cellular 
energy levels which may lead to AMPK activation (Figure 3, Figure 8, Figure 9), it is 
conceivable that the latter observation be achieved by 1,25(OH)2D3-mediated induction in 
intracellular calcium levels, due to increased expression of TRPV6. 
 
Conversely, regulation of calcium homeostasis by vitamin D might involve non-classical 
mechanisms, namely influencing energy metabolism. 1,25(OH)2D3 elevates circulating Ca2+ 
levels through increasing its renal and intestinal absorption, as well as by inducing osteoclast 
formation [3]. The latter mechanism, involves induction of RANKL (receptor activator of 
nuclear factor kappa-Β ligand) expression in osteoblasts, which binds to its receptor RANK on 
pre-osteoclasts, inducing their maturation to osteoclasts, which in turn increase serum levels of 
phosphorus and calcium by removing them from bones [3]. Recent studies have illustrated that 
metabolic alterations occur during osteoclast differentiation [128], with both glycolysis and 
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oxidative phosphorylation reported to be induced during RANKL-mediated osteoclast 
differentiation [129]. Similarly, mitochondrial dysfunction through deletion of Ndufs4—an 
essential subunit of mitochondrial complex I—was found to disrupt differentiation of 
osteoclasts [130]. On the other hand, osteoblasts have also been shown to exhibit a unique 
metabolic profile, which similar to cancer cells, is characterized by increased glycolysis even 
in the presence of oxygen [128]. Interestingly, a recent study by Esen et al. [131] illustrated that 
parathyroid hormone (PTH), which stimulates bone formation as well as 1,25(OH)2D3 renal 
production, triggers profound metabolic changes in osteoblast-lineage cells, through inducing 
insulin-like growth factor-1/mTOR complex 2 signaling. The authors illustrated that PTH 
treatment induces aerobic glycolysis in cells, and that pharmacological induction of 
mitochondrial metabolism dampens PTH’s anabolic effect on bones [131].  Therefore, taken 
together, these studies demonstrate that cellular metabolism is critical to both bone resorption 
and formation. Given 1,25(OH)2D3’s direct and indirect roles in regulating bone health [132], 
as well as its negative feedback regulation of PTH production and secretion [3], it is possible 
that metabolic changes underlie vitamin D-mediated bone remodeling. A better understanding 
of such mechanisms would lead to the optimal use of vitamin D compounds in diseases such as 
osteoporosis.     
 
3.2. TXNIP: a bystander, a “conditional” tumor suppressor, or a 
potential oncogene? 
 
An unexpected result in the early investigations of this thesis was the strong reduction in TXNIP 
protein expression with 1,25(OH)2D3 treatment in LNCaP cells (Figure 10). The initial 
hypothesis was that the decrease in glucose uptake in calcitriol-treated LNCaP cells was 
mediated through increased TXNIP expression, given the protein’s first identification as the 
VDUP1 and its role as a negative regulator of glucose uptake [88, 93]. However, it appeared 
that TXNIP protein levels are negatively regulated by 1,25(OH)2D3 due to possible hampering 
of transcriptional induction on one hand, and protein degradation on the other. Similar effects 
were observed in MCF-7 breast cancer cells (Figure 22), demonstrating the occurrence of this 
regulation in experimental systems previously used to advocate vitamin D’s anti-cancer effects 
[114, 115, 133]. Moreover, in other cell lines, calcitriol treatment had no effect on TXNIP 
protein levels (Figure 34), which not only questions the identity of the protein as one that is 
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upregulated by vitamin D treatment, but also its importance in mediating the anti-cancer effects 
of 1,25(OH)2D3.  
 
The view of TXNIP as a putative tumor suppressor originates from in-vitro, pre-clinical and 
clinical studies that demonstrate that: i) its expression is reduced/silenced in different tumor 
types, and ii) its expression induces oxidative stress-mediated apoptosis, cell cycle arrest, and 
inhibits mTOR signaling [108, 109]. While these are convincing arguments for TXNIP’s tumor 
suppressing roles, the protein’s influence on redox status could also be viewed from a pro-
survival perspective, since targeting ROS homeostasis in cancer treatment is bi-directional 
[134]. In other words, cancer cells are known to exhibit higher levels of ROS compared to their 
non-cancerous counterparts [134], making them more susceptible to ROS-modulating drugs. 
Therefore, targeting this homeostasis by anti-oxidants (e.g. TXNIP inhibitors) or pro-oxidants 
(e.g. TXNIP inducers) inhibits tumor cell survival [134].  
 
In this regard, I posit that inhibition of TXNIP may also be a viable therapeutic option, 
particularly in cancer cells that maintain the protein’s expression, as well as have particularly 
high ROS levels secondary to tissue-specific hormone- or growth factor-signaling. For 
example, numerous studies have demonstrated the involvement of AR-signaling in the 
oxidative stress observed in hormone-dependent prostate cancer [135]. In this regard, different 
studies have shown that treatment of LNCaP cells with androgens induces intracellular ROS 
levels [136, 137], whereas Pathak et al. [138] illustrated that dihydrotestosterone induces 
oxidative DNA damage in LNCaP cells (hormone-dependent), but not in DU145 or PC3 cells 
(hormone-independent). Additionally, the authors demonstrated that treating LNCaP-grafted 
mice with the anti-androgen flutamide significantly reduces oxidative DNA damage [138]. 
Similarly, in a study conducted by Miyake et al. [139], prostate cancer patients receiving 
hormonal therapy exhibited lower urinary levels of 8-hydroxy-2'-deoxyguanosine—a marker 
of oxidative DNA damage—compared to the levels observed before commencement of 
treatment. Despite these results, a clear mechanistic link connecting the AR to ROS homeostasis 
is missing.  
 
In this thesis, I show that LNCaP cells, which are AR-positive/hormone-sensitive prostate 
cancer cells, exhibit detectable TXNIP protein levels under basal conditions (Figure 10), and 
that genetic or pharmacological inhibition of the AR leads to a reduction in TXNIP protein 
expression (Figure 15 and Figure 16). Although I did not experimentally link AR modulation 
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to ROS homeostasis in my studies, I propose that regulating the activity/expression of members 
of the thioredoxin system, such as TXNIP, may be a mechanism through which AR-signaling 
aberrations drive cancer growth and proliferation.  
 
The other example of reduction in TXNIP protein expression by calcitriol is MCF-7 cells 
(Figure 22), which are luminal breast cancer cells, i.e. express ER and respond to hormone 
therapy, e.g. tamoxifen. Of note, is that estrogen and its metabolites, similar to androgens, have 
been shown to induce intracellular ROS levels, an effect known to contribute to the 
transformation and survival of breast cancer cells [140]. Given vitamin D’s well-characterized 
role as an anti-estrogen signaling molecule, via reducing ER alpha and aromatase expression 
[9], it is possible that the calcitriol-mediated reduction in TXNIP expression, and potentially 
ROS levels, serves as an additional mechanism dampening estrogen signaling. Additionally, at 
least in MCF-7’s case, the induction in G6PD expression and activity by calcitriol (Figure 29), 
may also lead to enhanced cellular anti-oxidant capacity, due to the increase in NADPH 
generation. Evidence supporting the inhibition of TXNIP as an anti-cancer strategy comes from 
the study by Song et al. [141], who demonstrated that reduction in VDUP1 expression using 
antisense cDNA, reduces intracellular ROS levels as well as inhibits proliferation of in-vitro 
and in-vivo melanoma models.  
 
These notions are intriguing and certainly warrant additional investigations, since results of 
studies investigating the efficacy of various antioxidants in cancer therapy have been so far 
contradicting. On one hand, N-acetylcysteine and vitamin C have been shown to inhibit tumor 
growth in preclinical models [142]. On the other hand, results of the Selenium and Vitamin E 
Cancer Prevention Trial (SELECT) illustrated that dietary vitamin E supplementation 
significantly increases the risk of prostate cancer in men [143].  
  
Furthermore, I propose that TXNIP’s role in glucose-sensing traps it in a crossfire between 
potential anti-cancer agents that limit glucose uptake or activate AMPK signaling, such as 
phloretin and metformin, respectively, and those that induce TXNIP levels, such as 
suberoylanilide hydroxamic acid, the histone deacetylase inhibitor [118]. It would therefore be 
exciting to study the effect of combining such TXNIP “activators” and “inhibitors” on anti-
cancer activities.  
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Inhibition of TXNIP has also been shown to possess beneficial effects in other diseases, such 
as diabetes, where studies have illustrated elevated TXNIP expression in muscles of pre-
diabetic and diabetic individuals on one hand [144], as well as induction of pancreatic beta cell 
apoptosis [145], an important step in type 1 and type 2 diabetes development [117], by the 
protein on the other. Moreover, it has been shown that TXNIP and insulin negatively regulate 
each other’s expression [146, 147], and that genetic/pharmacological inhibition of TXNIP in 
pancreatic beta cells protects from both type 1 and type 2 diabetes [117]. Furthermore, 
verapamail, a calcium channel blocker, has been shown to reduce TXNIP expression and beta 
cell apoptosis, elevate endogenous levels of insulin, and finally, protect mice from 
streptozotocin-induced diabetes [148]. Considering the established epidemiological link 
between diabetes and cancer [149], it is tempting to link diabetes-associated TXNIP induction 
to tumorigenesis. Interestingly, hyperinsulinemia, which is proposed to be one of the underlying 
molecular mechanisms linking diabetes to cancer [149], does not appear to impede diabetic 
hyperglycemia-induced TXNIP induction [117], highlighting the possibility that repeated and 
sustained post-prandial elevation in blood glucose levels, typically observed in pre-diabetics, 
may lead to a consistent, long-term increase in TXNIP levels, which may override, in terms of 
TXNIP regulation, the hyperinsulinemia observed in some type 2 diabetics. Furthermore, 
metformin, which is the most widely prescribed drug for type 2 diabetics and a putative anti-
cancer drug [70], is known to exert beneficial effects via insulin-dependent and –independent 
mechanisms [70], which may have contrasting effects on TXNIP expression. As an inhibitor of 
mitochondrial respiratory chain complex I [70], metformin increases cellular AMP:ATP ratio 
leading to AMPK activation, which induces TXNIP phosphorylation and subsequent 
degradation [94]. Additionally, metformin induces cellular glucose uptake and inhibits 
gluconeogenesis, thus lowering blood glucose levels and improving insulin resistance [70]. 
Although this has not been investigated, the subsequent lowering of circulating insulin levels 
in response to metformin treatment may lead to stabilization of cellular TXNIP levels, however, 
it should be noted that normal/basal levels of TXNIP are not linked to dysfunctional beta cells, 
but rather enhanced expression [117]. Thus, normalization—but not depletion—of TXNIP 
levels is proposed to be beneficial to diabetes therapy [117].     
 
With regards to TXNIP regulation by vitamin D, the data presented here clearly illustrate that 
the anticipated positive regulation of TXNIP expression by 1,25(OH)2D3 is not universal 
(Figure 34). However, it remains a possibility that the TXNIP gene contains functional VDRE, 
and that their accessibility by the VDR-RXR heterodimer is subject to chromatin architecture. 
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Although promoter analysis of the mouse VDUP1 gene failed to show the presence of VDRE 
[95], a different study predicted putative VDRE in the human TXNIP gene, however, the 
functionality of this site has not been shown [118]. 
 
Moreover, a clear distinction should be made between potential transcriptional regulation of the 
TXNIP gene by 1,25(OH)2D3 treatment, and actual elevation/stabilization in protein 
expression. Stambolsky et al. [86] demonstrated that mutant p53 converts the VDR from a 
tumor suppressor into a survival-promoting agent. In cells harboring mutant p53, the authors 
illustrated that calcitriol treatment reduces mRNA levels of TXNIP, a pro-apoptotic molecule 
[86]. On a similar note, the negative regulation of c-Myc by calcitriol shown in different 
publications [27, 97], could lead to differential regulation in TXNIP mRNA levels. Thus, 
transcriptional regulation of the TXNIP gene in cancer cells by calcitriol is subject to the cells’ 
genetic background. On the other hand, assuming transcriptional induction by 1,25(OH)2D3 as 
a prelude to increased TXNIP protein levels, the stability/activity of this protein is subject to 
diverse processes also influenced by vitamin D compounds, such as various protein degradation 
machinery [110], as well as by different kinases, namely AMPK and Akt [7, 78]. Moreover, 
TXNIP mRNA stability may also be targeted by vitamin D compounds post-transcriptionally, 
since microRNA expression has been shown to be regulated by vitamin D treatment [150]. Of 
interest, is that microRNA-17, which has been shown to inhibit TXNIP expression [117], has 
also been shown to be reduced in LNCaP cells by calcitriol treatment [133], indicating the 
possible stabilization of TXNIP mRNA levels by 1,25(OH)2D3, possibly leading to an increase 
in protein levels. 
 
Moreover, the functional consequences of putative TXNIP activation by 1,25(OH)2D3 may be 
subject to its cellular localization, which may be dictated by other effects of the treatment. For 
example, it has been recently shown that TXNIP, which had been repeatedly identified as a 
cytoplasmic protein, resides in the nucleus of pancreatic beta cells under basal conditions, and 
shuttles to the mitochondria in response to oxidative stress, where it binds to thioredoxin-2, 
disrupting its association with apoptosis signal-regulating kinase 1, leading to the latter’s 
activation and ultimately mitochondrial-dependent apoptosis [151]. In light of vitamin D’s 
regulation of redox-related genes [87, 152, 153], such mechanism may underscore the 
functional outcome of TXNIP induction by calcitriol, where mitochondrial localization of the 
protein in response to treatment-induced oxidative stress may dampen its role in glucose-
sensing.  
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3.3. Concluding remarks and future perspectives. 
 
This thesis clearly demonstrates previously unrecognized effects of calcitriol in transformed 
cells. Demonstrating the regulation of energy metabolism in tumor cells by treatment 
undoubtedly contributes to the evidence linking vitamin D to cancer treatment. However, 
despite encouraging in-vitro and pre-clinical results that continue to accumulate, extrapolation 
of vitamin D-based therapies to the clinic is in a stalemate. I propose that an improved, or 
perhaps a broader understanding of vitamin D’s cellular effects would lead to its optimal 
exploitation clinically. As a start, a strong distinction needs to be made between the “vitamin 
D-transcriptome” and the “vitamin D-proteome”, since vitamin D-regulated genes may be 
subject to either treatment-induced post-translational modifications—potentially altering 
protein stability and/or function—or simply not translated to proteins in the first place. The 
former possibility is tightly linked to vitamin D’s non-genomic effects on cell signaling [8], in 
which modulation of the activity of various signaling molecules by treatment, may lead to 
altered activity and stability of vitamin D-target genes. Moreover, effects of vitamin D on the 
expression levels of proteins may be largely independent of the classical transcriptional 
induction. To further clarify, vitamin D may alter the expression of putative target genes post-
transcriptionally, for example, through regulating the expression of mRNA-stabilizing or –
destabilizing non-coding RNAs like microRNAs, which have been shown to be regulated by 
vitamin D treatment [150]. Additionally, VDR activators may influence target protein stability 
and activity through inducing post-translational modifications, as previously mentioned, by: i) 
regulating the activity of various kinases, such as AMPK [78], which would lead to target 
protein phosphorylation, and/or ii) by inducing the expression of different E3 ligases [110], 
such as ITCH, which would enhance the ubiquitination and subsequent degradation of target 
proteins. Through these mechanisms, vitamin D treatment may indirectly influence the protein 
expression of numerous genes that had previously been undetected by classical cDNA 
microarray screens. A good example of such regulation is that of TXNIP by 1,25(OH)2D3 in 
prostate and breast cancer cell lines described in this thesis.  
 
Furthermore, I posit that hypercalcemia and tissue mineralization associated with the supra-
physiological doses of calcitriol may not be the sole side effects hampering the molecule’s use. 
For example, AMPK signaling induction by 1,25(OH)2D3, secondary to either increases in 
AMP:ATP ratio or intracellular Ca2+ levels, may impede the overall anti-cancer outcome, since 
this may lead to the activation of survival-promoting pathways such as autophagy [60]. These 
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possibilities should not discourage the use of calcitriol in oncological settings, but rather prompt 
further investigations into the different options enabling the bypassing or targeting of these 
pathways. An example of such approach is the use of an inhibitor of de novo serine synthesis 
in combination with 1,25(OH)2D3 to counteract the possible compensatory increase in serine 
synthesis in response to calcitriol’s effect on serine uptake in breast cancer cells. Therefore, a 
clearer picture of vitamin D’s cellular effects, both “the good” and “the bad”, would 
substantially increase the chances of success of vitamin D-based chemotherapies in clinical 
trials.  
  
In the context of this thesis, I propose that studying the metabolic effects of 1,25(OH)2D3 on 
different tumor types would elucidate ways to enhance the molecule’s efficacy. For example, 
in the case of prostate cancer cells, where calcitriol treatment was found to activate AMPK 
signaling, which is known to promote survival in such cells [127], either potentiating or 
counteracting this effect pharmacologically may enhance the molecule’s efficacy. Noteworthy 
is that this pathway appears not to be activated by 1,25(OH)2D3 in all investigated cancer cell 
lines, since it was not observed in experiments performed on MDA-MB-231 and HL-60 cells, 
as described in previous sections (Figure 22 and Figure 47). This does not tightly correlate 
with a lack of metabolic rewiring induced by treatment, as is the case in HL-60 cells, since 
MDA-MB-231 cells exhibited clear metabolic changes in response to 1,25(OH)2D3, nor does it 
correlate with the presumed canonical increase in intracellular Ca2+ levels—and subsequent 
signaling events—by calcitriol treatment. I hypothesize that AMPK signaling activation by 
VDR activators is largely dependent on cells’ genetic background, for example, p53 status. 
Within the scope of the investigations described in this thesis, AMPK induction was observed 
in cancer cells harboring wild-type p53 (MCF-7 and LNCaP), but not in those with a mutant 
form (MDA-MB-231) or those lacking p53 (HL-60). This possibility is intriguing and warrants 
further investigations, since p53 has been shown to trans-activate AMPK β1/2 [154], and 
AMPK has been shown to phosphorylate p53 at serine 15, inducing its stabilization [155]. 
Therefore, in wild-type p53-harboring cells, putative increases in intracellular Ca2+ levels in 
response to 1,25(OH)2D3 treatment could lead to a clearer, more sustained activation of AMPK, 
due to the bidirectional regulation of AMPK and p53.    
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4. MATERIALS AND METHODS 
 
4.1. Materials  
 
4.1.1. Chemicals 
 
Table 2: List of chemicals used in the described experiments. 
CHEMICAL SUPPLIER 
1,25(OH)2D3 Cayman Chemical, Biomol GmbH, 
Germany 
10058-F4 Sigma-Aldrich, Germany 
2-Deoxyglucose Fluka-Sigma-Aldrich, Germany 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
Carl Roth GmbH, Germany 
5-FU Fluka, Sigma-Aldrich, Germany 
AICAR Adipogen, Biomol GmbH, Germany 
Ammonium persulfate AppliChem, Germany 
Aprotinin AppliChem, Germany 
BAPTA-AM Cayman Chemical, Biomol GmbH, 
Germany 
Bovine serum albumin (BSA) Carl Roth GmbH, Germany 
Bromophenol blue AppliChem, Germany 
Calcipotriol Cayman Chemical, Biomol GmbH, 
Germany 
Casodex Santa Cruz Biotechnology, Heidelberg, 
Germany 
CBR-5884 Cayman Chemical, Biomol GmbH, 
Germany 
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Chloroform Zentralbereich Theoretikum 
Chemikalienlager, Heidelberg University. 
CHX Fluka-Sigma-Aldrich, Germany 
Compound C Calbiochem, Germany 
DHEA Cayman Chemical, Biomol GmbH, 
Germany 
DMSO  Sigma-Aldrich, Germany  
Ethanol VWR Chemicals, Germany 
Ethylenediaminetetraacetic acid (EDTA) Merck, Germany 
Glucose Sigma-Aldrich, Germany 
Glucose-6-phosphate (G6P) Sigma-Aldrich, Germany 
Glycerol Sigma-Aldrich, Germany 
Glycine Sigma-Aldrich, Germany 
Isopropanol Zentralbereich Theoretikum 
Chemikalienlager, Heidelberg University. 
KCl AppliChem, Germany 
L-Glutamine Gibco, Germay 
Leupeptin AppliChem, Germany 
Metformin HCl Sigma-Aldrich, Germany 
Methanol (absolute) Sigma-Aldrich, Germany 
MG-132 Sigma-Aldrich, Germany  
MgCl2 Sigma-Aldrich, Germany 
Milk Carl Roth GmbH, Germany 
Na Oxamate Cayman Chemical, Biomol GmbH, 
Germany 
Na3VO4 AppliChem, Germany 
Na4P2O7 AppliChem, Germany 
NaCl AppliChem, Germany  
NADP+ Sigma-Aldrich, Germany 
NaF AppliChem, Germany 
o-dianisidine Sigma-Aldrich, Germany 
Pepstatin AppliChem, Germany 
Phenol red Sigma-Aldrich, Germany 
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Phenylmethane sulfonyl fluoride (PMSF)  AppliChem, Germany 
Phloretin Sigma-Aldrich, Germany  
Rotiphorese® Gel 30/ Acrylamide mix Carl Roth GmbH, Germany 
Sodium dodecyl sulfate (SDS) Merck, Germany 
ß-mercaptoethanol Merck, Germany 
STO-609 Cayman Chemical, Biomol GmbH, 
Germany 
Testosterone Sigma-Aldrich, Germany 
Tetramethylethylenediamine (TEMED) Carl Roth GmbH, Germany 
Trichloroacetic acid VWR Chemicals, Germany 
Tris Carl Roth GmbH, Germany 
Tris-HCl Carl Roth GmbH, Germany 
Triton X-100 Carl Roth GmbH, Germany 
Tween 20 Carl Roth GmbH, Germany 
Urea Carl Roth GmbH, Germany 
 
4.1.2. Commercially-available reagents, kits, and consumables 
 
Table 3: List of commercially-available reagents, kits, and consumable used in the described 
experiments. 
ITEM SUPPLIER 
2-NBDG Cayman Chemical, Biomol GmbH, 
Germany  
Acid-washed glass beads (diameter 425-600 µm) Sigma-Aldrich, Germany 
ATPliteTM 1 step kit Perkin Elmer, Germany 
BD FACSFlow™ Becton Dickinson, Germany 
BD™ FACSclean Becton Dickinson, Germany 
Black 96-well microplate (clear bottom) Costar®, Corning Incorporated, USA 
Bradford Reagent Sigma-Aldrich, Germany 
Cell culture flasks (T-25, -75, -175) Greiner Bio-One, Germany 
Cell culture petri-dishes  Greiner Bio-One, Germany 
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Cell culture plates (6-, 12-, 24-, 48-, and 96- well 
plates) 
Greiner Bio-One, Germany 
Dihydroethidium (DHE) Cayman Chemical, Biomol GmbH, 
Germany 
DMEM (without NaHCO3 and glucose) Pan-Biotech GmbH, Germany 
Dulbecco’s Modified Eagle Medium (DMEM)-
GlutaMAX™ 
Gibco, Germay 
Dulbecco’s Phosphate-Buffered Saline (D-PBS) Gibco, Germay 
Eppendorf tubes (1.5 and 2.0 mL) Greiner Bio-One, Germany 
FACS tubes Becton Dickinson, Germany 
Falcon/Centrifuge tubes Greiner Bio-One, Germany 
Fetal Calf Serum (FCS) Gibco, Germay 
GOx Sigma-Aldrich, Germany 
Horseradish peroxidase (HRP) Sigma-Aldrich, Germany 
HydroDish® PreSens Precision Sensing GmbH, 
Germany 
JC-1 Sigma-Aldrich, Germany 
LightCycler® 480 SYBR Green I Master  Roche, Germany 
Lipofectamine® 3000 Thermo Fischer, Germany 
MitoTracker Green Thermo Fischer, Germany 
Opti-MEM Reduced Serum Medium Gibco, Germany 
OxoDish® PreSens Precision Sensing GmbH, 
Germany 
PageRuler™ Prestained Protein Ladder Nippon Genetics Europe GmbH, 
Germany 
Parafilm® M Sigma-Aldrich, Germany 
Penicillin-streptomycin Gibco, Germay 
Polyvinylidene fluoride (PVDF) membranes GE Healthcare, Germany  
Ponceau S Sigma-Aldrich, Germany 
ProtoScript® II first strand cDNA synthesis kit New England Biolabs, Germany  
QIAzol lysis reagent Qiagen, Germany  
RPMI 1640 without glucose Gibco, Germany 
RPMI 1640-GlutaMAX™ Gibco, Germany 
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Sensorchips SC1000 Bionas, Rostock, Germany 
Serological pipettes (2.0, 5.0, 10.0, 25.0 mL) Costar corning incorporated 
SRB sodium salt Santa Cruz Biotechnology, Germany 
Syringe filters (0.2 µm pore size) GE Healthcare, Germany 
Syringes (50 mL) Becton Dickinson, Germany 
TrypLE™ Express  Gibco, Germay 
Western LightningTM Plus-ECl Perkin Elmer, Germany 
Whatman™ 3mm CHR (45x57 cm) GE Healthcare, Germany 
 
4.1.3. Instruments 
 
Table 4: List of instruments used to perform the described experiments. 
INSTRUMENT SUPPLIER 
AccuBlock Tm Digital Dry Bath Labnet International, Inc., NJ, USA 
Analytical balance 440-33N Kern und Sohn, Balingen, Germany 
BIONAS 2500 Bionas, Rostock, Germany 
BlueFlash-L SERVA Electrophoresis GmbH, 
Germany 
Centrifuge 5415R Eppendorf, Germany 
Centrifuge 5702 Eppendorf, Germany 
Centrifuge 5804 Eppendorf, Germany 
Enduro™ Power Supplies  Labnet International, Inc., NJ, USA 
FACS Calibur Becton Dickinson, Germany 
Hemocytometer Brand, Wertheim, Germany 
HERA cell 150i incubator Thermo Scientific, Germany 
LAS3000 Imaging System FujiFilm, Germany 
Micropipettes (10, 20, 100, 200, 1000 µL) Eppendorf, Germany 
Microscope CKX41 Olympus Life Science, Germany 
Miltidrop Combi Thermo scientific, Germany 
Mixer mill MM 300 Retsch, Germany 
Multichannel pipettes (100 and 200 µL) Eppendorf, Germany 
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NanoDrop 2000 spectrophotometer Thermo scientific, Germany 
Orbital shaker/Belly Dancer Stovall Life Science Inc., NC, USA 
Pipetboy Integra Biosciences, Germany 
Power Station 200 Labnet International, Inc., NJ, USA 
Problot hybridization oven Labnet International, Inc., NJ, USA 
Real-time thermal cycler qTower Analytik Jena AG, Germany 
Roller mixer SRT6 Stuart, Germany 
SensorDish® Readers (SDRs) PreSens Precision Sensing GmbH, 
Germany 
Spectrafuge Mini Labnet International, Inc., NJ, USA 
Tecan Infinite F200 Pro Tecan, Germany 
Tecan Ultra plate reader Tecan, Germany 
Thermomixer comfort  Eppendorf, Germany 
Vacuum pump ZM Engineering, Apolda, Germany 
VIAFLO ASSIST automated multi-channel 
pipettes 
Integra Biosciences, Germany 
Vortex-Genie®2 Scientific Industries, Inc., NY, USA 
Water bath  GFL, Germany 
 
 
4.1.4. Buffers and solutions 
 
Table 5: List/recipes of buffers/solutions used in the described experiments. 
Buffer/solution Ingredient Concentration 
Bionas RM Glucose 
L-Glutamine 
Penicillin 
Streptomycin 
HEPES 
FCS 
Phenol red 
1 g/L 
2 mM 
100 U/mL 
100 µg/mL 
1 mM 
0.1 % 
15 µg/L 
- 
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DMEM (without 
NaHCO3 and glucose) 
Lysis buffer for SDS- 
Polyacrylamide gel 
electrophoresis 
(PAGE) 
Urea 
EDTA 
Triton X-100 
NaF 
Pepstatin 
Leupeptin 
Aprotinin 
PMSF 
Na3VO4 
Na4P2O7 
in D-PBS 
6 M 
1 mM 
0.5 % 
5 mM 
10 µg/mL 
10 µg/mL 
3 µg/mL 
100 µM 
1 mM 
2.5 mM 
- 
5X Gel loading buffer SDS 
ß-mercaptoethanol 
Bromophenol blue 
Glycerol 
Tris HCl 
in distilled water 
4% 
200 mM 
0.2% 
20 % 
10 mM 
- 
SDS-PAGE running 
buffer 
Tris HCl 
Glycine 
SDS 
in distilled water 
25 mM 
250 mM 
0.1% 
- 
Tris-glycine SDS-
Polyacrylamide gel 
(10%) 
30% Acrylamide mix 
1.5 M Tris (pH 8.8) 
10% SDS 
10% Ammonium 
persulfate 
TEMED 
Water 
33% 
25% 
1% 
1% 
 
0.04% 
40% 
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Stacking gel for Tris-
glycine SDS-
polyacrylamide gel 
(5%) 
30% Acrylamide mix 
1.0 M Tris (pH 6.8) 
10% SDS 
10% Ammonium 
persulfate 
TEMED 
Water 
17% 
12.5% 
1% 
1% 
 
0.1% 
68% 
Anode buffer Methanol 
Tris HCl 
in distilled water 
10 % 
0.3 M 
- 
Cathode buffer Methanol 
Tris HCl 
in distilled water 
10 % 
25 mM 
- 
TBS/Tween NaCl 
KCl 
Tris HCl 
Tween 20 
in distilled water 
8 g/L 
0.2 g/L 
3 g/L 
0.1 % 
- 
GOx enzyme mix GOx 
Tris pH 8.0 
HRP 
o-dianisidine 
50 mg/L 
250 mM 
40 mg/L 
100 mg/L 
G6PD enzyme mix KCl 
Tris HCl 
MgSO4 
in distilled water 
100 mM 
50 mM 
5 mM 
- 
Lysis buffer for crude 
extracts 
HEPES 
EDTA 
MgCl2 
KCl 
in distilled water 
20 mM 
1 mM 
5 mM 
100 mM 
- 
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4.1.5. Computer software 
 
Table 6: List of computer software used in performing experiments/analyzing data. 
SOFTWARE SUPPLIER 
BIONAS analysis software Bionas, Rostock, Germany 
CellQuest Pro Analysis Software Beckton Dickinson, NJ, USA 
GraphPad PRISM GraphPad Software Inc., CA, USA 
Image Reader LAS-3000 Fujifilm, Germany 
ImageJ National Institutes of Health, Maryland, USA 
Microsoft Excel Microsoft, WA, USA 
NanoDrop 2000 software Thermo Scientific, Germany 
qPCRsoft 3.1 Analytik Jena, Germany 
SDR_v38 software PreSens Precision Sensing GmbH, Germany 
 
4.1.6. Cell lines 
 
Table 7: List of all cell lines used in the described experiments. 
CELL LINE SUPPLIER 
LNCaP (human prostate cancer) ATCC, Manassas, USA 
VCaP (human prostate cancer) ATCC, Manassas, USA 
DU145 (human prostate cancer) ATCC, Manassas, USA 
PC3 (human prostate cancer) ATCC, Manassas, USA 
MCF-7 (human breast cancer) ATCC, Manassas, USA 
MDA-MB-231 (human breast cancer) ATCC, Manassas, USA 
HL-60 (human acute promyelocytic leukemia) ATCC, Manassas, USA 
Jurkat (human acute T cell leukemia) ATCC, Manassas, USA 
U937 (human histiocytic lymophoma) ATCC, Manassas, USA 
HCT116 (human colorectal cancer) ATCC, Manassas, USA 
HT-29 (human colorectal cancer) ATCC, Manassas, USA 
HepG2 (human hepatocellular cancer) ATCC, Manassas, USA 
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HLE (human hepatocellular cancer) Kind gift from Prof. Dr. 
Steven Dooley (Heidelberg 
University) 
SK-HEP-1 (human hepatocellular cancer) ATCC, Manassas, USA 
AsPC-1 (human pancreatic cancer) ATCC, Manassas, USA 
BxPC-3 (human pancreatic cancer) ATCC, Manassas, USA 
MIA PaCa-2 (human pancreatic cancer) ATCC, Manassas, USA 
 
4.1.7. Antibodies 
 
Table 8: List of all antibodies used in immunoblotting experiments. 
TARGET  VENDOR 
Anti-AR Cell Signaling Technology, New England Biolabs®, Frankfurt 
am Main, Germany 
Anti-c-Myc Cell Signaling Technology, New England Biolabs®, Frankfurt 
am Main, Germany  
Anti-G6PD Abgent, Inc. San Diego, CA, USA 
Anti-GLUT1 Cell Signaling Technology, New England Biolabs®, Frankfurt 
am Main, Germany 
Anti-ITCH Cell Signaling Technology, New England Biolabs®, Frankfurt 
am Main, Germany 
Anti-pACC (S79) Cell Signaling Technology, New England Biolabs®, Frankfurt 
am Main, Germany 
Anti-AMPK⍺  Santa Cruz Biotechnology, Heidelberg, Germany 
Anti-PDHK1 Cell Signaling Technology, New England Biolabs®, Frankfurt 
am Main, Germany 
Anti-ß-actin Santa Cruz Biotechnology, Heidelberg, Germany 
Anti-TXNIP (VDUP1) MBL International Corporation, Woburn, MA, USA  
Anti-Vinculin Santa Cruz Biotechnology, Heidelberg, Germany  
HRP-linked anti-mouse IgG Cell Signaling Technology, New England Biolabs®, Frankfurt 
am Main, Germany 
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HRP-linked anti-rabbit IgG Cell Signaling Technology, New England Biolabs®, Frankfurt 
am Main, Germany 
 
4.1.8. Primers  
 
Table 9: List of primers, all of which were synthesized by Eurofins Genomics (Germany), 
used for RT-qPCR experiments described in this thesis. Lyophilized primers obtained were 
dissolved in defined volumes of nuclease-free water, indicated by the manufacturer, to obtain a 
final concentration of 100 pmol/µL. For RT-qPCR, primers were further diluted (1:20) in water.  
PRIMER NAME PRIMER SEQUENCE 
ACACA-For 5'-GATTCGTTGTCATGGTCACACC-3' 
ACACA-Rev 5'-GTTGTTGTTTGGTCCTCCAGG-3' 
ACLY-For 5'-GCATCTATGCCACCCGAGAAG-3' 
ACLY-Rev 5'-CCAACAAGCAGCTTCTGGGC-3' 
AMPKb1-For 5'-GTCGCTGAGGGGTGGTGAAG-3' 
AMPKb1-Rev 5'-CTCGCAATCGCGCTTTACCTG-3'  
AR-For 5'-ACATGGTGAGCGTGGACTTT-3' 
AR-Rev 5'-GAGCTGGGGTGGGGAAATAG-3' 
ATP5B-For 5'-GGAGTCTAGAGGATCCACAGC-3' 
ATP5B-Rev 5'-CCCTGCCCCTGCTACTACG-3' 
BAD-For 5'-CGGAGGATGAGTGACGAGTT-3'  
BAD-Rev 5'-CCAAGTTCCGATCCCACCAG-3'  
BAX-For 5'-GGGGACGAACTGGACAGTAA-3' 
BAX-Rev 5'-CAGTTGAAGTTGCCGTCAGA-3' 
                                   MATERIALS AND METHODS 
 81 
BECN1-For 5'-GCTGAAGACAGAGCGATGGTA-3' 
BECN1-Rev 5'-GGACGTCTTAGACCCTTCCA-3' 
COX5B-For 5'-CCAGCGTCGTCTGGTTTTGG-3' 
COX5B-Rev 5'-GCTCAGTGTGCCAGCTGCT-3' 
CS-For 5'-CTCAAAAGAGTGGGCAAAGAGG-3' 
CS-Rev 5'-CTGCACTGAGCTGAGACATGG-3' 
CYP24A1-For 5'-TGGGGCTGGGAGTAATACTGA-3' 
CYP24A1-Rev 5'-GAACGCAATTTCATGGGAGGC-3' 
CYTC-For 5'-GAAGTGTTCCCAGTGCCACAC-3' 
CYTC-Rev 5'-TCCAGGGGCCTGACCTGTC-3' 
FASN-For 5'-CCTGAGGCCCAACACGCAG-3' 
FASN-Rev 5'-GCTTCTGCACGGCCTCAGG-3' 
G6PD-For 5'-CCAAGAACATTCACGAGTCCTG-3' 
G6PD-Rev 5'-GGACAGCCGGTCAGAGCTC-3' 
GLS1-For 5'-CCTCAACTGGCCAAATTCAGTC-3' 
GLS1-Rev 5'-CTGAAGACAGAAGGGAACTTTG-3' 
GLS2-For 5'-GCTTTCCTAAGGGGGTGGAC-3' 
GLS2-Rev 5'-GTGGCTGCCATGACACTGC-3' 
GLUT1-For 5'-CAGTTTGGCTACAACACTGGAG-3' 
GLUT1-Rev 5'-GCAGGATGCTCTCCCCATAG-3' 
GOT1-For 5'-CACGAGTATCTGCCAATCCTG-3' 
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GOT1-Rev 5'-CCTACCCGCTTCTCCTTGAG-3' 
HKII-For 5'-GTGGCACCCAGCTGTTTGAC-3' 
HKII-Rev 5'-CGAGAAGGTAAAACCCAGTGG-3' 
IDH1-For 5'-CGACCAAGTCACCAAGGATG-3' 
IDH1-Rev 5'-GAACTCCTCAACCCTCTTCTC-3' 
ITCH-For 5'-5TCTAGTAGCTGTGGTCGGGG-3' 
ITCH-Rev 5'-CACAAGGCCACCGTGAAATG-3' 
KLK3-For 5'-AGTGCGAGAAGCATTCCCAA-3' 
KLK3-Rev 5'-CCCAGCAAGATCACGCTTTT-3' 
LDHA-For 5'-GAAGGGAGAGATGATGGATCTC-3' 
LDHA-Rev 5'-CTTATCTTCCAAGCCACGTAGG-3' 
LKB1-For 5'-ATGGAGTACTGCGTGTGTGG-3' 
LKB1-Rev 5'-GGTACTCCAGGCCGTCAATC-3' 
MYC-For 5'-TTCGGGTAGTGGAAAACCAG-3' 
MYC-Rev 5'-CAGCAGCTCGAATTTCTTCC-3' 
NDUFA1-For 5'-GAGATTCTCCCCGGACTCTC-3' 
NDUFA1-Rev 5'-CCCTTTTTTCCTTGCCCCCG-3' 
OGDH-For 5'-GGTAGAAGCACAGCCCAACG-3' 
OGDH-Rev 5'-CTGTGCTACATGGTGCCCTC-3' 
P21-For 5'-GACACCACTGGAGGGTGACT-3' 
P21-Rev 5'-CAGGTCCACATGGTCTTCCT-3' 
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PDHA1-For 5'-CCCCACAGACCATCTCATCAC-3' 
PDHA1-Rev 5'-CCTTTTCGTCCTGTAAGCTCTG-3' 
PDHK1-For 5'-GGATCGATTCTACATGAGTCGC-3' 
PDHK1-Rev 5'-GTTTTCGATGAGATGGACTTCC-3' 
PGC1A-For 5'-GACAGATGGAGACGTGACCAC-3' 
PGC1A-Rev 5'-CTTAAGTAGAGACGGCTCTTCTG-3' 
PKM2-For 5'-CAGAGGCTGCCATCTACCAC-3'  
PKM2-Rev 5'-GAGGACGATTATGGCCCCAC-3'  
PUMA-For 5'-GACGACCTCAACGCACAGTA-3' 
PUMA-Rev 5'-CACCTAATTGGGCTCCATCT-3' 
SDHC-For 5'-GGACAACCACTCCAGACTGG-3' 
SDHC-Rev 5'-GGACAACCACTCCAGACTGG-3' 
SREBP1-For 5'-CATTGAGCTCCTCTCTTGAAGC-3' 
SREBP1-Rev 5'-GGGTACATCTTCAATGGAGTGG-3' 
TFAM-For 5'-TGTCTGACTCTGAAAAGGAAGTGA-3'  
TFAM-Rev 5'-ACATGAATCAAGCCTTGCCC-3'  
TIGAR-For 5'-AAGTGGTGTGGGGGAGGTAG-3'  
TIGAR-Rev 5'-CGGACAACAGTCAGAGCGAA-3'  
TSC2-For 5'-CGTAGGCTACCCCGAGCA-3'  
TSC2-Rev 5'-CAGACAGATTTCTCGTCCGC-3' 
TXNIP-For 5'-CGCCTCCTGCTTGAAACTAAC-3' 
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TXNIP-Rev 5'-AATATACGCCGCTGGTTACACT-3' 
VCL-For 5'-CAGTCAGACCCTTACTCAGTG-3' 
VCL-Rev 5'-CAGCCTCATCGAAGGTAAGGA-3' 
VDR-For 5'-TGGAGACTTTGACCGGAACG-3'  
 VDR-Rev 5'-GGGCAGGTGAATAGTGCCTT-3'  
VEGFA-For 5'-GGAGACCTGGTTGTGTGTGTG-3' 
VEGFA-Rev 5'-GCACGTGGATCCTGCCCTG-3' 
 
4.1.9. siRNA  
 
Table 10: List of siRNAs used in RNA interference experiments. siRNAs listed below have 
been synthesized by Riboxx (Riboxx GmbH, Radebeul, Germany). 
 
 
 
 
TARGET SENSE (5'-3') ANTISENSE (5'-3') 
AMPKα1 GGGGGCCACAAUCAAAGAUAU 
GGGGGAUUGGAACAUGAUUUA 
GGGGGAGAGCUAUUUGAUUAUA 
AUAUCUUUGAUUGUGGCCCCC 
UAAAUCAUGUUCCAAUCCCCC 
UAUAAUCAAAUAGCUCUCCCCC 
AR GGGGGCUACUCUUCAGCAUUAUU 
GGGGGACUCAGCUGCCCCAUCCA 
GGGGGACGCUUCUACCAGCUCAC 
AAUAAUGCUGAAGAGUAGCCCCC 
UGGAUGGGGCAGCUGAGUCCCCC 
GUGAGCUGGUAGAAGCGUCCCCC 
                                   MATERIALS AND METHODS 
 85 
4.2. Methods  
 
4.2.1. Cell culture 
  
All cell lines listed in Table 7 were maintained in DMEM GlutaMAX™ supplemented with 
10% (v/v) FCS and 1% (v/v) penicillin/streptomycin, with the exception of suspension cell 
lines, namely HL-60, Jurkat, and U937, which were maintained in RPMI GlutaMAX™ medium 
also supplemented with FCS and penicillin/streptomycin, at 10% and 1% (v/v), respectively. 
Culture flasks were kept in a standard cell culture incubator, set at 37°C with 5% CO2 and 
appropriate humidity. Cellular proliferation was monitored microscopically, and cell lines were 
passaged upon reaching 70-80% confluency. Adherent cell lines were sub-cultured by 
aspirating the consumed medium, washing once with D-PBS, and incubating with TrypLE™ 
Express inside the incubator for 3-5 mins. Detached cells were then harvested in standard 
DMEM and transferred to a 15 mL falcon tube, spun down for 3 mins at 300 g in a centrifuge. 
Medium on top of the cellular pellet was aspirated, and fresh medium was used to re-suspend 
the pellet. Medium containing a known cell number, depending on the culture flask used, was 
then transferred back to the flask containing fresh medium. Suspension cells were passaged by 
harvesting them from the culture flask and transferring them to a 15 mL falcon tube, after which 
the same protocol used for the adherent cells was applied. Adherent cells were seeded in 
designated culture plates one day prior to treatment, and treatments were performed in fresh 
medium, whereas suspension cells were seeded and treated on the same day. Concentrations of 
drugs used as well as the treatment periods are indicated in both the corresponding methods 
subsection and/or the results section.   
   
4.2.2. RNA extraction, cDNA synthesis, and RT-qPCR 
 
For RNA extraction, different cell lines were seeded at varying densities in culture plates, 
depending on cells’ proliferation rate and the duration of treatment. At the end of the treatment 
period, consumed medium was aspirated from adherent cells, and cells were washed once with 
D-PBS. For suspension cells, cells were harvested and transferred to 2.0 mL Eppendorf tubes, 
which were subsequently centrifuged at 300 g for 5 mins. Consumed medium was then 
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aspirated and the cellular pellet washed once with D-PBS, after which the tubes were 
centrifuged once again under the same conditions. 150 µL of QIAzol lysis reagent were added 
to each well (adherent cells) or Eppendorf tube (suspension cells), and incubated at room 
temperature for 5 mins. In the case of adherent cells, lysates were then transferred to 1.5 mL 
Eppendorf tubes for further steps. 30 µL of chloroform were then added to each tube, which 
were vortexed for 15 secs, and placed on ice for 15 mins. Tubes were then centrifuged at 13,000 
g for 15 mins at a temperature of 4°C. The upper aqueous phase of the resulting biphasic 
solution was transferred to a fresh 1.5 mL Eppendorf tube, and RNA was precipitated using 75 
µL isopropanol per tube. Tubes were then incubated at room temperature for 10 mins, after 
which they were centrifuged under the same conditions (13,000 g; 15 mins; 4°C).  The solution 
was then discarded, and the RNA pellet was washed twice with 150 µL of 70% (v/v) ethanol in 
water. After a final centrifugation step (7,500 g; 5 mins; 4°C) and the discarding of ethanol, 30 
µL of RNase free water were used to dissolve the RNA pellet. The concentration and purity of 
the resulting RNA samples were assessed by the NanoDrop 2000 UV-Vis Spectrophotometer.  
 
cDNA was synthesized from 500 ng of RNA of each sample, using the ProtoScript® II first 
strand cDNA synthesis kit. RT-qPCR was performed using synthesized cDNA (1.0 µL), 
primers listed in Table 9 (1.0 µL), reaction mix LightCycler® 480 SYBR Green I Master (2.5 
µL), and nuclease-free water (0.5 µL), in a total reaction volume of 5 µL. The thermal cycler 
conditions comprised an initial denaturation step at 95°C for 5 mins, followed by 45 cycles of 
denaturation (95°C; 10 secs), annealing (60°C; 10 secs), and elongation (72°C; 20 secs). 
Melting curve analysis was performed at the end of every PCR run, and wells yielding false 
positive signals were excluded from further analyses. The ∆∆Ct method was used to calculate 
the relative mRNA expression of genes in response to treatment, with vinculin used as the 
housekeeping gene.   
 
4.2.3. RNA interference 
 
LNCaP and MCF-7 cells were transiently transfected with the designated siRNAs, listed in 
Table 10, as well as a NC, by adding 50 pmol of siRNA/well in a 24-well plate, containing 100 
µL/well of Opti-MEM Reduced Serum Medium. 1.5 µL/well Lipofectamine® 3000 were added, 
and the plate was left to incubate for 20 mins. Following this, 60,000 cells suspended in 500 
µL of DMEM without antibiotics were added to each well, and the contents of the wells were 
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gently mixed by re-suspending using a micropipette. Knock-down efficiency was then 
confirmed by western blotting.  
 
4.2.4. On-line monitoring of cellular metabolism  
  
The Bionas 2500 biosensor chip system was used to assess the influence of 1,25(OH)2D3 
treatment on energy metabolism of prostate and breast cancer cells. This system enables on-
line measurements of acidification and oxygen consumption rates, which reflect glycolytic and 
respiratory rates, respectively, as well as impedance, which acts as an indicator of cellular 
viability and adhesion. This system has been previously used to investigate the influence of 
various drugs on energy metabolism of different cancer cell lines [156, 157]. Experimentally, 
cells were seeded on sensor chips (SC1000) at a density of 200,000 cells/chip in 450 µL of full 
medium/chip. Six sensor chips were then transferred to the Bionas system on the following day 
and the experiment was commenced. The composition of the RM used is described in Table 5, 
with the main feature being the presence of a weak buffering system (1 mM HEPES), to enable 
rapid detection of minor fluctuations in the medium’s acidification in response to cellular lactate 
production, as well as being less nutrient- and growth factor-rich compared to the cell culture 
medium used in the other experiments, to prevent excessive cellular growth and proliferation 
on chip. RM was introduced to the system in 8 min cycles, with 4 mins of pumping (at a rate 
of 56 µL/min) and 4 mins of stagnation, allowing for measurements. Untreated RM was 
introduced to the cells in this manner for an initial 6 h, to enable stabilization of the 
measurements, and to allow the cells to acclimate to the new environment. Treated medium 
contained 0.1% (v/v) of either 1,25(OH)2D3 (reaching a final concentration of 100 nM) or 
DMSO, and was introduced to the system at the same described rate, for a total period of 72 h. 
Finally, a recovery period was included in which cells were subjected again to untreated RM 
for approximately 20 h.  
  
To analyze changes in metabolic parameters of HL-60 cells, HydroDish® and OxoDish® 24-
well plates were used, which measure medium pH (reflecting lactate production/glycolysis) and 
amount of dissolved oxygen in the medium (reflecting respiration), respectively. Cells were 
seeded at a density of 20,000 cells/well in 1.0 mL of RPMI GlutaMAX™ medium, and plates 
were subsequently placed on SDRs present in a standard cell culture incubator. The experiment 
was subsequently commenced, with measurements taken once every 3 mins. Cells remained 
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untreated for an initial 20 min period, to enable signal stabilization, after which measurements 
were halted, and the plates were taken out of the incubator for treatment. 1,25(OH)2D3 and 
DMSO treatments were performed as described above, and additional controls were included, 
namely the glycolysis inhibitor 2-deoxyglucose (10 mM) and the mitochondrial complex I 
inhibitor metformin (2 mM), for pH and oxygen consumption measurements, respectively. 
Moreover, wells containing medium without cells were also included as a NC. After treatment, 
the plates were returned to the incubator and placed on SDRs, and the measurements were 
continued.     
 
4.2.5. SRB assay 
 
SRB assay was performed to investigate the effect of various treatments on cellular 
proliferation. Cells were seeded in 96-well plates at a density of 5,000 cells in 200 µL 
medium/well. The plates were treated the following day, and at the end of the treatment period, 
100 µL/well of ice-cold trichloroacetic acid were added. Plates were then incubated at 4ºC for 
1 h, after which contents were discarded, and the plates washed with water three times, and 
placed in a hybridization oven set at 65ºC for 30 mins. 100 µL/well of SRB solution (0.057 % 
(w/v) SRB in 1 % (v/v) acetic acid in water) were then added, and the plates were incubated for 
30 mins at room temperature. SRB solution was then discarded, and the wells washed three 
times with 200 µL/well 1 % acetic acid, and the solution discarded after each time. The plates 
were then dried in a hybridization oven (65ºC; 30 mins), after which the dye was solubilized 
using 10 mM Tris buffer pH 10.5 (200 µL/well). To ensure complete solubility of the dye, the 
plates were placed in a thermomixer for 5 mins (25 ºC; 300 rpm), and the absorbance of wells 
was measured at 535 nm in a plate reader. Changes in cellular proliferation in response to 
treatments were calculated by normalizing the absorbance of drug-treated wells to that of 
DMSO-treated wells.   
 
4.2.6. Enzymatic assays: GOx and G6PD activity measurements 
 
Levels of glucose in the medium were determined using the GOx assay. 50,000 cells in 0.5 mL 
medium/well were added to 48-well plates and treated with 1,25(OH)2D3 (100 nM) for different 
time points. At the end of the treatment period, 10 µL of the supernatant were collected, and 
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glucose standards of varying concentrations (0.1-1.0 g/L glucose in water) were prepared. Both 
samples and standards were diluted 10 times, and 5 µL of each sample and standard were mixed 
with 240 µL of the GOx enzyme mix (described in Table 5) in 96-well plates. Plates were then 
incubated at room temperature for 1 h, after which the absorbance of the samples was measured 
at 450 nm using a plate reader. The calibration curve constructed from the absorbance obtained 
from the different standards was used to calculate the concentration of glucose in the medium 
of cells treated with either DMSO or 1,25(OH)2D3. SRB assay was performed for normalization 
of the results. 
  
For the analysis of G6PD activity, MCF-7 cells were seeded in petri-dishes (100 x 20 mm) at a 
density of 1,000,000 cells/dish in 10 mL of medium/dish, and treated the following day with 
either DMSO or 1,25(OH)2D3 (100 nM) for a period of 72h. Cells were subsequently harvested, 
washed once with D-PBS, centrifuged for 3 mins at 300 g, the D-PBS aspirated, and the cellular 
pellet placed on ice. 500 µL of lysis buffer for crude extracts (described in Table 5) were used 
to re-suspend the pellet, and 200 mg of acid-washed glass beads (diameter 425-600 µm) were 
added to the suspension. Cells were subsequently lysed using a bead mill (1-2 min; 30 Hz), and 
then placed immediately on ice. The supernatant was then collected by centrifuging the samples 
(5 mins; maximum speed; 4°C), and Bradford assay was performed to determine protein 
concentration. Briefly, 200 µL/well of Bradford reagent were added to 96-well plates. 2 µL of 
each sample were added to each well, with each sample pipetted in 3 technical replicates. 
Additionally, 2 µL/well lysis buffer were also added to wells containing Bradford reagent, to 
serve as the blank in the spectrophotometric measurement. BSA standards (100-1500 µg/mL) 
were also prepared and similarly added to wells containing Bradford reagent, to provide data 
points for a calibration curve. After 10 mins of incubation on a Thermomixer (300 rpm) at 25°C, 
the absorbance of the samples was measured at 595 nm using a plate reader.  
 
500 ng of total protein per sample were added to a solution containing the G6PD reaction 
mixture described in Table 5, together with 0.5 mM G6P and 1 mM NADP+, reaching a total 
volume of 100 µL. The absorbance of the samples was kinetically monitored at 345 nm using 
a plate reader. The reduction of NADP+ to NADPH by G6PD results in an increase in 
absorbance, and the rate of increase correlates with the enzyme’s activity.   
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4.2.7. FACS analysis of intracellular ROS, mitochondrial mass/membrane 
potential, and glucose uptake  
 
For FACS experiments, cells were seeded in 6-well plates at a density of 200,000 cells/well in 
2.0 mL of medium. Suspension cells were treated on the same day, while adherent cells were 
treated the following day in fresh medium. Cells were treated with DMSO or 1,25(OH)2D3 (100 
nM) for the designated treatment period, after which the experiment was started. 250,000 cells 
were harvested from each well, spun down (3 min; 300 g), and the medium discarded, for the 
analysis of either intracellular ROS, mitochondrial mass or membrane potential. For 
intracellular ROS determination, 500 µL of DMEM without phenol red, containing DHE at a 
final concentration of 15 µM, were used to resuspend the cellular pellet, and then incubated for 
15 mins in the dark with mild shaking. The samples were then spun down in a centrifuge (3 
min; 300 g) and the medium containing DHE was carefully discarded. The cellular pellet was 
then re-suspended in 500 µL of DMEM without phenol red and FACS analysis was performed 
using the FL-2 channel.  
 
For mitochondrial mass and membrane potential measurements, the initially harvested cellular 
pellet (approximately 250,000 cells) was washed once with D-PBS, and spun down (3 min; 300 
g). Cells were then re-suspended in 500 µL DMEM without phenol red containing either 7.5 
nM MitoTracker Green or 2 µM JC-1, for the analysis of mitochondrial mass and membrane 
potential, respectively. The medium used to dissolve MitoTracker Green also lacked FCS. Cells 
were incubated with the dyes for 30 mins, after which cells were spun down in a centrifuge (3 
mins; 300 g), and the medium discarded. The cellular pellet was finally re-suspended in 500 µL 
DMEM without phenol red and FACS analysis was performed. FL-1 and FL-2 channels were 
used for the detection of JC-1 monomers and J-aggregates, respectively, and the FL-1 channel 
was used to assess mitochondrial mass in cells. The FL-2:FL-1 ratio positively correlated with 
mitochondrial membrane potential.  
 
The glucose uptake experiment was performed by replacing the culture medium of cells at the 
end of the treatment period with medium containing 50 µM 2-NBDG. For adherent cells, the 
procedure involved aspirating the old culture medium and immediately replacing it with fresh 
medium containing the fluorescently-labelled glucose analog. Suspension cells on the other 
hand were harvested, spun down (3 min; 300 g), and then re-suspended in the new 2-NBDG-
containing medium. Culture plates were subsequently placed back in a standard incubator for 
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2 h, after which cells were harvested, spun down (3 min; 300 g), and re-suspended in 500 µL 
of DMEM without phenol red. Intracellular levels of 2-NBDG were then assessed by FACS, 
using the FL-1 channel.  
 
4.2.8. Western blotting 
 
Cells were seeded in 6-well plates at a final density of 500,000 cells/well in 2 mL medium/well, 
and treated with the various molecules at the concentrations and for the time periods indicated 
in the text. At the end of the treatment period, the old medium was gently aspirated, and cells 
were washed once with D-PBS (2 mL/well). After aspirating the D-PBS, 90 µL of lysis buffer 
for SDS-PAGE described in Table 5 were added to each well, and the culture plates were placed 
on ice for approximately 5 mins. Cellular lysates were then transferred to fresh 1.5 mL 
Eppendorf tubes, and spun down in a centrifuge set at 4°C for 15 mins at maximum speed. The 
supernatants were then transferred to fresh 1.5 mL Eppendorf tubes, and the protein 
concentration of samples was determined by Bradford assay.  
  
For western blot sample preparation, volumes of cell lysates corresponding to equal amounts 
of proteins (approximately 50 µg) were mixed with 5x gel loading buffer, the composition of 
which is described in Table 5, and the volumes of the samples were normalized using 6M urea 
buffer. Samples were then denatured by placing them in a thermomixer set at 65°C for 10 mins. 
Equal sample volumes were then loaded on SDS-PAGE gels (composition described in Table 
5), and gel electrophoresis was run (100 V; 2 h).  
 
Proteins were then transferred by semi-dry blotting. Filter papers and PVDF membranes were 
cut in the exact dimensions of the gel. 3 filter papers were soaked in anode buffer (composition 
in Table 5) and sequentially placed on the anode plate of the transfer machine, with careful 
removal of trapped air bubbles with the addition of each layer. A PVDF membrane, first 
activated by brief incubation in methanol, was immersed in anode buffer and then placed on 
the filter paper stacked layers. The gel, first immersed in cathode buffer (composition in Table 
5), was then carefully placed on top of the membrane. 3 additional layers of filter papers, soaked 
in cathode buffer, were placed on top of the gel, one after the other, carefully eliminating 
trapped air bubbles between the layers to ensure efficient transfer. A current of 2.5 mA/cm2 was 
subsequently applied for 30 mins. At the end of the transfer, the PVDF membrane was carefully 
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removed from the transfer sandwich and washed once with 1x Tris-buffered saline 
(TBS)/Tween for 5 mins on an orbital shaker. The membrane was then incubated with Ponceau 
S solution for 10 mins on an orbital shaker, after which mild washing with TBS/Tween was 
applied, and the transfer efficiency documented by imaging. The membrane was then washed 
several times with TBS/Tween, until the Ponceau S stain was completely removed, and then 
the membrane was incubated with blocking solution, composed of 5% (w/v) non-fat dry milk 
in TBS/Tween, for at least 1-2 h at room temperature on an orbital shaker. Afterwards, the 
membrane was washed once with TBS/Tween before overnight incubation at 4°C with the 
primary antibody, which was diluted in a solution of 5% (w/v) BSA in TBS/Tween (dilutions 
employed were those recommended by the supplier). The membrane was then washed once 
with TBS/Tween on an orbital shaker, and then incubated for 1 h with anti-mouse or –rabbit 
HRP-linked secondary antibody, dissolved in a ratio of 1:5000 in 5% (w/v) non-fat dry milk in 
TBS/Tween. The membrane was then washed 3 times with TBS/Tween, 5 mins each time on 
an orbital shaker. Target bands were visualized by the LAS3000 Imaging System, using a 
commercially available enhanced chemiluminescence solution.  
 
4.2.9. GC/MS-based metabolite quantification 
 
GC/MS experiments were kindly performed by Dr. Michael Büttner (Metabolomics Core 
Technology Platform, Center for Organismal Studies, Heidelberg University). A clear 
description of the followed protocol is available in reference [90]. LNCaP, MCF-7, and MDA-
MB-231 cells were seed in cell culture petri-dishes (145x20 mm) at an initial density of 
2,000,000 cells/dish, in 15 mL of full medium. The following day, the medium was replaced 
with DMSO- or 1,25(OH)2D3 (100 nM)-treated medium, and the petri-dishes were then placed 
in a standard incubator for 72 h. At the end of the treatment period, the medium was aspirated, 
the dishes placed on ice, and cells were washed with 10 mL ice-cold 0.9% (w/v) NaCl in water. 
The saline was then carefully aspirated, and 1.2 mL of saline was added to each dish, and used 
to harvest cells by scraping. Cells were transferred to fresh 1.5 mL Eppendorf tubes, re-
suspended several times, and a 50 µL aliquot of each sample was set aside for total cell number 
determination. Tubes were then spun down in a centrifuge (300 g; 5 mins), and the supernatant 
carefully discarded. The samples were then shock-frozen by placing the tubes in liquid nitrogen, 
and were subsequently stored in a -80ºC until analysis.           
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4.2.10. Statistical analyses 
 
Microsoft Excel and GraphPad Prism were used for statistical analyses. A two-tailed Student’s 
t-test was used to compare between treated and untreated cells, with p-values less than or equal 
to 0.05 identified as statistically significant. *, **, and *** are used to depict p-values less than 
or equal to 0.05, 0.01, and 0.001, respectively. Error bars represent the SD, unless otherwise 
stated in the figure legend.  
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